


 Cite this: *RSC Adv.*, 2023, 13, 24353

# *Moringa oleifera* Lam.: a comprehensive review on active components, health benefits and application†

 Xinyue Su,<sup>‡a</sup> Guanzheng Lu,<sup>‡a</sup> Liang Ye,<sup>a</sup> Ruyu Shi,<sup>a</sup> Maomao Zhu,<sup>a</sup> Xinming Yu,<sup>a</sup> Zhiyong Li,<sup>\*b</sup> Xiaobin Jia<sup>\*a</sup> and Liang Feng<sup>ID \*a</sup>

*Moringa oleifera* Lam. is an edible therapeutic plant that is native to India and widely cultivated in tropical countries. In this paper, the current application of *M. oleifera* was discussed by summarizing its medicinal parts, active components and potential mechanism. The emerging products of various formats such as drug preparation and product application reported in the last years were also clarified. Based on literature reports, the unique components and biological activities of *M. oleifera* need to be further studied. In the future, a variety of new technologies should be applied to the development of *M. oleifera* products, to enrich the varieties of dosage forms, improve the bitter taste masking technology, and make it better for use in the fields of food and medicine.

Received 29th May 2023

Accepted 21st July 2023

DOI: 10.1039/d3ra03584k

[rsc.li/rsc-advances](https://rsc.li/rsc-advances)

## Introduction

*Moringa oleifera* Lam. (*M. oleifera*), also known as drumstick or horseradish, is a perennial tree that belongs to the Moringaceae family.<sup>1</sup> It is considered to be a medicine food homology plant with great medicinal values and was introduced into Yunnan province, China, in the 1960.<sup>2</sup> *M. oleifera*, acquainted with “Tree of Wonders”, “Tree of Life” and “Diamond of Plants”, is widely cultivated for its drought resistance, rapid growth and nutrient-rich properties in African and Asian countries.<sup>3</sup> (Fig. 1). *M. oleifera* is a remarkable plant with multiple edible parts, each offering unique biological activities. Its leaves, fruit pods, fruits, seeds, flowers, and roots all contribute to its versatility and potential benefits. And in India and Africa, it is commonly used to treat diabetes, skin diseases, hyp immunity, arthritis, cancer, and so on.

The safety of *M. oleifera* is closely related to its ingredients, therefore, an increasing number of scholars have focused on the identification of the active compounds for the investigation of its pharmacological effects and potential mechanisms which are crucial in the process of *M. oleifera* application of drugs and food products development. It is of great significance and value to explore the relationship between its ingredients and efficacy, the determination of key ingredients, the selection of different

dosage forms and the toxicity evaluation of *M. oleifera* on the human body. Fortunately, studies on *M. oleifera* have been conducted and numerous new active ingredients were found, leading to the developments of new preparation methods, pharmacological efficacies and toxicological effects of *M. oleifera*. What's more, the underlying molecular mechanism of *M. oleifera* action is also being revealed.<sup>4</sup>

This article summarized the past 10 years of research on the medicinal parts, active ingredients, health benefits and the mechanisms, dosage forms and applications of *M. oleifera*. In addition, we also use UPLC-Q-TOF-MS, network pharmacology and molecular docking to analyse the components and pharmacological mechanisms. This article summarizes and explains the chemical composition and biological activity and mechanisms of action of *M. oleifera*. It predicts trends in the expansion of *M. oleifera* products and formulation design with a focus on innovation and diversification, aiming to provide theoretical support and research ideas for subsequent studies. In this way, this paper provides not only a basic research summary but also a comprehensive future research plan for *M. oleifera*. Furthermore, the challenges and future trends of *M. oleifera* are summarized to provide a research approach for the further development and application.

## *M. oleifera* related article acquisition based on CiteSpace

This study regards the Web of Science Core Collection as a data-collection platform according to data resources required in CiteSpace. The bibliometric search strategy can be described as the following: topics = (“*Moringa oleifera* Lam. OR *Moringa*

<sup>a</sup>School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China. E-mail: jiaxiaobin2015@163.com; wenmoxiushi@163.com

<sup>b</sup>Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, P. R. China. E-mail: lizhiyong7899@sina.com

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ra03584k>

‡ These authors contributed equally to this work.






Fig. 1 Key distribution areas of *M. oleifera* worldwide (the dots indicate the presence of *M. oleifera* in this area. Images were obtained from <https://www.gbif.org/>).

*oleifera* OR Moringa”), time span = 2012–2023, and language = English.<sup>5</sup> We used the 6.1.R6 version of CiteSpace software to analyse the current hot spots of *M. oleifera*.

We searched 5249 publications related to *M. oleifera*. (Fig. 2A) Bergamasco Rosangela was the most prolific author

with most publications, *i.e.*, with 60 articles (Fig. 2B). The India, Egypt and China were the leading country and the top institution in this field of study, with 725, 372 and 348 articles, respectively (Fig. 2C). There was active cooperation between institutions, countries, and authors. Hot topics focused on




Fig. 2 CiteSpace, the Java application, can be used to generate knowledge-domain visualization. Annual trend chart of publications (A). The network of author and countries in the study area of insomnia and circadian rhythm (B and C). Timeline diagram of keywords in the field of *M. oleifera* (D).



*Moringa oleifera* leave, *Moringa oleifera* extract, antioxidant activity, and oxidative stress (Fig. 2D).

## Medicinal parts of *M. oleifera*

The whole plant of *M. oleifera* including leaf, fruit pod, fruit, seed, flower and root, all have a variety of biological activities, and can even play medicinal roles in preventing and treating diseases.

The leaves of *M. oleifera* are rich in resources and easily harvested which mainly contain active components such as polyphenols, flavonoids, phenylpropanoids, terpenoids, fatty acids, alkanes, sterols, as well as minerals and vitamins.<sup>6</sup> Among them, polyphenols and flavonoids are the main bioactive constituents, with antioxidant activity and anticancer properties,<sup>7</sup> antiseptics,<sup>8</sup> anti-inflammatory,<sup>9</sup> anti-hypertension, anti-diabetes, anti-spasm, reduce metal toxicity,<sup>10</sup> reduces plasma and liver lipids and affects obesity-related reproductive





Fig. 3 Polyphenols in *M. oleifera*. [1] Cinnamic acid, [2] *p*-coumaric acid, [3] caffeic acid, [4] ferulic acid, [5] isoferic acid, [6] sinapic acid, [7] vanillic acid, [8] syringic acid, [9] gallic acid, [10] protocatechuic acid, [11] gentiolic acid, [12] chlorogenic acid, [13] niazirin, [14] salvianolic acid A, [15] salvianolic acid B, [16] quinic acid, [17] ellagic acid, [18] procyanidin, [19] rosmarinic acid, [20] chicoric acid, [21] epicatechin, [22] 4-*O*-caffeoylquinic acid, [23] 3,4-di-*O*-caffeoylquinic, [24] 4-methyl-( $\alpha$ -L-rhamnose pyranoxy)-carbamate.



diseases<sup>11</sup> and anti-epilepsy,<sup>9</sup> affect reproductive diseases<sup>12</sup> and other activities.

The seeds of *M. oleifera* are mainly composed of protein, fatty and flavonoids, and essential amino acids required by the human body.<sup>13–15</sup> Furthermore, the isothiocyanates contained in *M. oleifera* seeds also play a crucial role in anti-inflammatory,

antioxidant, antibacterial and anticancer.<sup>16</sup> And the essential oil has coagulant effect that can accelerate wound healing.<sup>17</sup>

While previous research on *M. oleifera* mainly focused on the leaves and seeds, there has been limited discourse on its stems. Methanol reflux method and column tomography were used to extract four compounds, namely cholest-5-en-3-ol, stigmasterol,




Fig. 4 Flavonoids in *M. oleifera*. [25] Vitexin, [26] cirsiilol, [27] cirsimaritin, [28] cirsilineol, [29] apigenin, [30] luteolin, [31] acacetin, [32] vitexin, [33] vicenin 2, [34] isovitexin, [35] cosmosiin, [36] rutin, [37] kaempferol, [38] quercetin, [39] isorhamnetin, [40] myricetin, [41] quercitrin, [42] iso-quercitrin, [43] astragalol, [44] quercetin-3-O-(6''-acetyl-glucoside), [45] kaempferol-3-O-(6''-acetyl glucoside), [46] quercetin-3-O-(6-malondiyloxy)-β-D-glucopyranoside, [47] kaempferol-3-O-malondiacetylhexanoside, [48] quercetin-3-O-hydroxymethyl glutaryl galactoside, [49] kaempferol-3-O-hydroxymethyl glutaryl hexanoside, [50] catechin, [51] (–)-epicatechin, [52] naringenin, [53] naringin, [54] kaempferitrin, [55] myricitrin, [56] multiflorin-B, [57] multinoside A.



gamma-sitosterol, and tricosanoic acid, from the stem of *M. oleifera*. These fractions and the methanol extract showed strong antifungal activity against *Rhizoctonia solani* and *Fusarium oxysporum*.<sup>18</sup> The resulting fractions derived from different solvents such as hexane, benzene, chloroform, ethyl acetate, acetone and water have been found to have activities against *Rhizoctonia solani* and *Fusarium oxysporum*. *M. oleifera* flowers and fruits are rich in carbohydrates, proteins, organic acids, flavonoids and phenols. Singhal *et al.* recorded that tocopherols, ascorbic acid, carotenoids and flavonoids, are antioxidants and have the ability to eliminate reactive oxygen species (ROS).<sup>19</sup>

## Chemical components of *M. oleifera*

*M. oleifera* contains a variety of functional active ingredients, which underlie its use as a dietary supplement and functional food. The reported functional active ingredients and their specific effects in *M. oleifera* are summarized through comprehensive literature review by ChemDraw 19.0 (Fig. 3–8, Table 1).

According to research conducted by Tekayev *et al.* (2010) and Tesfaye *et al.* (2022), moringa leaves, flowers, seeds, and other nutritional parts are plentiful in multiple nutrients and can be utilized as both food and medicine.<sup>20,21</sup> In order to further explore and analyze the functional components and mechanism of the main nutrient parts of *M. oleifera*, the dry leaves and seeds (MOL and MOS) of *M. oleifera* were analysed by UPLC-Q-

TOF-MS. Manual calibration was performed to verify the accurate mass-to-charge ratio, secondary fragment ion information and literature data for each compound, identifying 33 MOL and 45 MOS components, respectively. Under the proposed analysis conditions, the total ion flow diagram of *M. oleifera* in positive and negative ion mode are shown in Fig. 9.

The compound of MOL includes 13 flavonoids, 5 phenolic acids, 6 amino acids, 3 phenylpropanoids, 2 phytosterols, 2 terpenoids (2 triterpenoid saponins) and 2 vitamins which are detailed in Table 2. The information of MOS obtained by identification is shown in the table below and includes 19 flavonoids, 11 phenolic acids, 5 amino acids, 7 phenylpropanoids, 1 terpenoid (1 triterpenoid saponin), 2 vitamins.

## Toxicity of *M. oleifera*

*M. oleifera* leaf extracts were tested by WST-1 assay with melanoma cells (A375 human malignant melanoma cell line, A2058 human metastatic melanoma cell line) and normal human dermal fibroblasts (NHDF, WS1).<sup>7</sup> The results showed that *M. oleifera* extract could inhibit the proliferation of both melanoma cells in a dose-dependent manner. However, *M. oleifera* extract had no significant inhibitory effect on both normal human somatic cells ( $IC_{50} > 200 \mu\text{g mL}^{-1}$ ), even at the highest concentration ( $200 \mu\text{g mL}^{-1}$ ), showed only mild cytotoxicity to normal cells after 48 h.




Fig. 5 Phenylpropanoids in *M. oleifera*. [58] Cinnamic acid, [59] (+)-isolariciresinol-3a-O- $\beta$ -D-glucopyranoside, [60] lariciresinol-9-O- $\beta$ -D-glucopyranoside, [61] (+)-pi-noresinol-4-O- $\beta$ -D-glucopyranoside, [62] lariciresinol, [63] (7S,8R)-dihydrodehydrodiguaiacyl alcohol, [64] medioresinol, [65] evofolin B, [66] 1-(4-hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2], [67] esculetin.










Fig. 7 Terpenoids in *M. oleifera*. [83] Neoxanthin, [84] violaxanthin, [85] lutein, [86] zeaxanthin, [87]  $\beta$ -carotene, [88] tricyclohumuladiol, [89] 3 $\beta$ -hydroxy-oleano-11,13(18)-diene-28-carboxylic acid, [90] oleanolic acid.

to inflammation and consequently to a variety of diseases such as pancreatitis,<sup>96</sup> periodontitis,<sup>97</sup> arthritis,<sup>98</sup> acute kidney injury,<sup>99</sup> colitis<sup>100</sup> and so on. Previous studies have suggested

that the flavonoids and polyphenols contained in *M. oleifera*, such as rutin and myricetin, are the main active ingredients that exert the antioxidant and anti-inflammatory functions.<sup>101</sup> In




Fig. 8 Glucosinolates and isothiocyanate in *M. oleifera*. [91] isobutyl isothiocyanate, [92] benzyl isothiocyanate, [93] 4-[( $\alpha$ -L-rhamnosyloxy)benzyl] isothiocyanate, [94] 4-[(2-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl] isothiocyanate, [95] 4-[(3-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl]isothiocyanate, [96] 4-[(4-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl] isothiocyanate, [97] 4-[( $\alpha$ -L-rhamnosyloxy)benzyl]glucosinolate, [98] 4-[(2'-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl]glucosinolate, [99] 4-[(3'-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl] glucosinolate, [100] 4-[(4'-O-acetyl- $\alpha$ -L-rhamnosyloxy)benzyl]glucosinolate.



Table 1 Bioactivities of the main components extracted from *M. oleifera*

| Number | Components  | Bioactivities                         | Diseases/tissues   | Effects and function  | Ref.               |
|--------|-------------|---------------------------------------|--|---|--------------------|
| 1      | Polyphenols | Antioxidant                           | Hypertension/<br>neurodegeneration   | Free radical scavenging activities  | 27 and<br>28<br>29 |
|        |             |                                       | Diabetes   | Inhibition of free radical, lipid peroxidation, cholinergic and monoaminergic activity<br>Inhibition of $\alpha$ -amylase activity  | 30 and<br>31       |
|        |             |                                       | Enhance sexual function and the male reproductive system<br>Anti-aging               | Scavenged DPPH radical, ABTS radical and $H_2O_2$ and suppressed the formation of LPO and AGEs<br>Reduce lipid peroxidation and lipofuscin pigmentation and increase serotonin and antioxidant enzymes in the brain of aged rats  | 32<br>33           |
|        |             |                                       | Other  | Caspase-dependent and caspase-independent apoptotic pathways mediated by mitochondrial ROS are involved<br>Reduce food intake, water intake and body weight, lower blood glucose levels and improve inflammation  | 27 and<br>34<br>35 |
|        |             |                                       | Anticancer<br>Metabolic syndrome   | Improve hyperglycemia, insulin resistance, inflammation, carbohydrate and lipid metabolism, non-alcoholic fatty liver   | 1 and<br>9         |
| 1      | Polyphenols | Antibacterial<br>Anti-inflammatory    | <i>S. aureus</i> , <i>Bacillus cereus</i>  | Bacterial cell damage and leakage of intracellular substances   | 36 and<br>37       |
|        |             |                                       | Arthritis  | Scavenging of free radicals, inhibition of protein denaturation, membrane stabilization and anti-proteinase activity  | 6, 9<br>and 38     |
|        |             |                                       | Cancer (colon cancer, lung cancer)<br>Hypolipidemic effects                          | By working directly on visceral mass and restoring mRNA expression of leptin, resistin, and adiponectin genes<br>Improve body weight, atherogenic index and insulin resistance in obese rats  | 27<br>30           |
|        |             |                                       | Diabetes   | Induced insulin secretion   | 30 and<br>31       |
|        |             |                                       | Myocardial damage<br>Reduce metal toxicity   | Decreased the apoptotic markers Bax, cytochrome-c and iNOS expression, induced NO level, and increased BCL <sub>2</sub> markers<br>Protect yeast cells against As(III) toxicity, likely through its role in decreasing As(III) accumulation and As(III)-induced ROS production, the hydroxyl and carboxyl groups of gallic acid appear to play a critical role in chelating As(III) inhibition of the accumulation of toxic metals in the body<br>ACE inhibition test showed ACE inhibition activity<br>Enhanced courtship behavior and reproductive function | 30<br>12           |
| 2      | Flavonoids  | Antihypertensive effects<br>Antiviral | Hypertension<br>Enhance sexual function and the male reproductive system<br>COVID-19 | High docking binding affinity for non-structural proteins nsp9 and nsp10 of COVID-19  | 39                 |





Table 1 (Contd.)

| Number | Components                        | Bioactivities  | Diseases/tissues   | Effects and function  | Ref.          |
|--------|-----------------------------------|--|--|---|---------------|
| 2      | Flavonoids                        | Regulate intestinal flora                              | Promote wound healing  | Regulate the proportion of digestive tract flora  | 40            |
|        |                                   | Promote the proliferation and migration of fibroblasts |  | Induced fibroblast proliferation and cell migration   | 41            |
| 3      | Fatty acids and plant sterols     | Antioxidant  | Hypolipidemic effects  | Improved body weight, total cholesterol, triglyceride and LDL levels in obese rats  | 30 and 42     |
|        |                                   | Anticancer   |  | Apoptotic cells can be significantly induced by changing mitochondrial membrane potential in EAC cell lines   | 43            |
| 4      | Glucosinolates and isothiocyanate | Antihypertensive effects                               | Hypertension MCF-7, HepG2 and HCT-116                                      | Reduce vascular oxidation in spontaneously hypertensive rats  | 30            |
|        |                                   | Anticancer   |  | Inhibition of IL-3 – induced STAT5 target gene expression. The isothiocyanate group of moringin should be necessary for its chemoprotective activities  | 42, 44 and 45 |
|        |                                   | Antioxidant  | Diabetes   | Lower body weight, reduce obesity, improve glucose tolerance, reduce inflammatory gene expression, increase antioxidant gene expression improved glucose tolerance and reduced obesity, inflammation and oxidative stress. Antibiotic-like recombination regulates the gut microbiome | 46            |
|        |                                   | Anti-inflammatory Antioxidant                          | Skin photoaging  | It is beneficial to the uptake of HaCaT cells, thus improving the activity of antioxidant enzymes, clearing UVB-induced ROS, protecting skin from damage, and reducing the expression of MMP-1, MMP-3 and MMP-9 caused by radiation-induced photoaging                                | 16            |
| 5      | Polysaccharides                   | Antibacterial  | <i>L. monocytogenes</i>  | Damage the integrity of cell walls and membranes, stimulate oxidative stress, interfere with energy metabolism and DNA replication  | 47            |
|        |                                   | Antioxidant  |  | DPPH radical scavenging activity removes excess free radicals from the system and protects them from oxidative damage   | 48–51         |
|        |                                   | Antidiabetic   |  | $\alpha$ -Amylase inhibition and $\alpha$ -glucosidase inhibition   | 48, 51 and 52 |
|        |                                   | Regulate intestinal flora                              |  | Increased villus height and mucosal thickness in the ileum, colon, and duodenum, as well as villus height and crypt depth ratio in the ileum. Boost the activity of digestive enzymes.  |               |
|        |                                   | Hypolipemia  | Hyperlipidaemia  | Improved the variety of the gut microbiota in mice  | 53            |
|        |                                   | Immunomodulatory effect                                |  | Effective bile acid sequestrants  |               |
|        |                                   | Anti-inflammatory                                      | Rheumatoid arthritis, inflammatory bowel disease, asthma, and pancreatitis | Enhanced pinocytic rate and increased production of ROS, NO, IL-6, and TNF- $\alpha$ levels   | 48, 51 and 54 |
|        |                                   | Anticancer   | Human ovarian cancer   | Inhibited the production of IL-6 and TNF- $\alpha$  | 51            |
|        |                                   | Antibacterial  | Wound healing  | Induce apoptosis of cancer cells and suppress cancer cell proliferation   | 49            |
|        |                                   |  |  | Promote wound contraction and internal tissue growth. It has highly potent and durable antibacterial activity against infectious pathogens in wounds  |               |



Table 1 (Contd.)

| Number | Components | Bioactivities   | Diseases/tissues                     | Effects and function   | Ref.           |
|--------|------------|---|--------------------------------------|--|----------------|
| 6      | Others     | Antibacterial<br>Anti-inflammatory<br>Antioxidant<br>Antihypertensive effects | <i>S. aureus</i><br><br>Hypertension | Irreversible membrane damage is caused to <i>S. aureus</i> cells by increasing membrane permeability, leading to the release of intracellular nucleotide pools<br>Inhibit DPPH and ABTS free radicals, and inhibit the production of NO<br><br>Reduction in systolic and diastolic blood pressure in spontaneously hypertensive rats | 55<br>56<br>57 |
| 6      | Others     | Antibacterial   | H1N1 virus                           | Inhibition of virus replication in host cells has a protective effect on infected cytopathies caused by IAVS   | 58 and 59      |

addition, isothiocyanates, which are abundant in the seeds of *M. oleifera*, also exhibit these effects both *in vitro* and *in vivo*.<sup>63</sup> The specific mechanism of the anti-inflammatory effect of MO may be through regulating the gene expression levels of inflammatory cytokines. These cytokines include interleukin-6 (IL-6), interleukin-17A (IL-17A), interleukin-4 (IL-4), interleukin-10 (IL-10), nitric oxide (NO), inducible nitric oxide synthase (iNOS) and interleukin-1 $\beta$  (IL-1 $\beta$ ). In addition, the gene expression of antioxidant factor (quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPX) and antioxidant enzyme (GSTP1)) is regulated to play the role of antioxidant (Fig. 10).

#### Antitumor effect


Cancer remains a major health concern with chemotherapy previously prescribed having significant side effects. The plant-based therapies have become a hot research topic in recent years. *M. oleifera* contains a variety of bioactive substances that have positive effects on the treatment for cancer.

*M. oleifera* leaves can fight against variety classes cancer cells. *M. oleifera* leaves water extract (MOE) has significant anticancer effect on melanoma cells *in vitro*, while it has almost no effect on normal human fibroblasts. The specific mechanisms of action involve mitochondrial-mediated Cleaved-Caspase and Caspase apoptosis pathway, indicating its potential for skin cancer treatment.<sup>102</sup>

Alkaloids, which are nitrogen-containing organic compounds, have demonstrated antitumor effects. *M. oleifera* alkaloids have been shown to inhibit PC3 cell proliferation and migration by inhibiting cyclooxygenase-2-mediated (COX-2-mediated) Wnt/ $\beta$ -catenin signaling pathway through *in vivo* and *in vitro* experiments. Lung cancer is one of the common malignant tumors. Studies have found that *M. oleifera* alkaloids also have therapeutic effects on lung cancer. Further experiment showed that *M. oleifera* can inhibit the proliferation and migration of human non small cell lung cancer cell (A549) cells by inhibiting the mechanisms related to activation of Janus kinase2/Signal Transducer and Activator of Transcription 3 (JAK2/STAT3) pathway, and induce cell apoptosis and cell cycle arrest, further highlighting its potential in preventing and treating lung cancer.<sup>4</sup>

#### Improve gut microbiota effect

The importance of gut microbiota in human health has been revealed by numerous studies in recent years. The imbalance of intestinal flora is associated with some diseases, such as diabetes, obesity, chronic kidney disease and colitis. *M. oleifera* seed extract (MSE) was given to male C57BL/6J mice for 16S of fecal/cecum samples after 12 weeks of feeding together with normal diet and high-fat diet rRNA gene sequencing and quantitative Polymerase Chain Reaction (PCR) showed major changes in intestinal microbiota and significant reduction of bacterial load, similar to antibiotic response, suggesting that *M. oleifera* seed extract can improve metabolic health through antibiotic-like recombination of intestinal microbiota,



**Fig. 9** Chromatographic analysis was performed on a Waters Acquity UPLC system, equipped with a binary pump solvent management system, an online degasser and an autosampler. All separations were carried out on an ACQUITY UPLC™ HSS T3 column (2.1 mm × 100 mm, 1.8 μm) at 45 °C. The mixture of (A) acetonitrile and (B) 0.1% (v/v) methanoic acid aqueous solution was chosen as the mobile phase using a gradient program: 0–2 min, 5–15% A; 2–8 min, 15–23% A; 8–11 min, 23–100% A; 11–13 min, 100–5% A; and stayed at 5% A for 4 min. The flow rate was 0.4 mL min<sup>-1</sup> and the injection volume was 2 μL. UPLC-Q-TOF-MS chromatogram of MOL in positive ionization mode (A), and in negative ionization mode (B); UPLC-Q-TOF-MS chromatogram of MOS in positive ionization mode (C), and in negative ionization mode (D).

meanwhile, MSE supplementation can reduce body weight, obesity and inflammatory gene expression, improve glucose tolerance, and increase antioxidant gene expression.<sup>46</sup> Wang *et al.* extracted the polysaccharide component MOS-2-A from *M. oleifera* leaves.<sup>103</sup> Through experiments, they verified that MOS-2-A could reduce the number of pathogenic bacteria by increasing the number of beneficial bacteria, significantly improve the diversity of intestinal flora in mice, improve the structure of intestinal flora, and help maintain the integrity of intestinal mucosa, promote digestion and promote intestinal health. *M. oleifera* leaves induce the production of acetic acid, propionic acid and n-butyric acid after gastrointestinal digestion and colonic fermentation *in vitro*, resulting in a decrease in pH and promoting the growth of beneficial colonic bacteria.<sup>40</sup> In addition, more experimental results reveal that *M. oleifera* has the ability to regulate intestinal for the treatment of diseases.

### Neuroprotective effect

Herbs therapy is widely used in the treatment of many diseases due to its low toxicity and good curative effect. *M. oleifera* has a variety of functions, including protective effects on the nervous system, due to its rich active ingredients.

*M. oleifera* is rich in flavonoids and polyphenols, which have neuroprotective effects. Di-(2-ethylhexyl) phthalate (DEHP) at specific concentrations can produce neurotoxic effects after prenatal and postnatal exposure. In rats, prenatal exposure to DEHP can disrupt the development of the central nervous system and reduce brain weight. It was found that *M. oleifera* extract can restore the activity of mitochondrial respiratory chain complex by regulating and reducing the formation of ROS, prevent oxidative injury by regulating Nrf2/HO-1 expression, and inhibit endoplasmic reticulum stress (ER stress)

response to prevent neuron injury and protect neurons SH-SY5Y cells were protected from DEHP-induced apoptosis and maintained mitochondrial membrane permeability and caspase-3 activation, thus realizing the neuroprotective effect of *M. oleifera* extract on DEHP injury. *M. oleifera* seeds are rich in glucosinolates, such as niazimicin (NZ), the main bioactive substance.<sup>104</sup> Abdelsayed *et al.* found that NZ in *M. oleifera* seeds can play a neuroprotective role by affecting oxidative stress marker glutathione (GSH), malondialdehyde (MDA) inflammatory mediators NF-κB and NO neurotransmitters, dopamine and 5-hydroxytryptamine, and brain fatty acids (FA) levels in AlCl<sub>3</sub>-induced dementia rats.<sup>105</sup>

### Ameliorate metabolic syndrome effect

Metabolic syndrome is a group of clinical syndromes with hypertension, central obesity, diabetes mellitus, hyperlipidemia and abnormal glucose metabolism. In modern times, people's life pressure, irregular work and rest, unreasonable diet structure and other factors lead to the low age of metabolic syndrome diseases, and become one of the main causes of death.<sup>106</sup> And studies have shown that *M. oleifera* can play a significant role in the treatment of these diseases.

Niazirin, a phenol glycoside isolated from *M. oleifera* seeds, could improve insulin resistance, hyperglycemia, hyperlipidemia, and non-alcoholic fatty liver disease. And in-depth investigation showed that niazirin can reduce the accumulation of gluconeogenesis and lipid, improve glycolysis and lipid oxidation by activating the AMP-Activated Protein Kinase (AMPK) pathway. These findings suggest that niazirin could serve as an effective treatment for metabolic syndrome.<sup>1</sup>

Additional studies have shown that *M. oleifera* leaf hydrolysate (MOLH), which is rich in phenols and peptides, can





Table 2 UPLC-Q-TOF-MS analysis of MOL and MOS

| No. | $t_R$ (min) | Ion type                                       | M/Z          |                   | Error | The total number of pieces (ppm)   | Formula  | Compound name   | Source |
|-----|-------------|--|--------------|-------------------|-------|--|--|---|--------|
|     |             |  | Actual value | Theoretical value |       |  |  |   |        |
| 1   | 0.56        | [M - H] <sup>-</sup>                           | 173.1042     | 174.1117          | -1.4  | 156.0773 (C <sub>6</sub> H <sub>10</sub> N <sub>3</sub> O <sub>2</sub> ), 131.0829 (C <sub>3</sub> H <sub>11</sub> N <sub>2</sub> O <sub>2</sub> )                               | C <sub>6</sub> H <sub>14</sub> N <sub>4</sub> O <sub>2</sub> | Arginine  | MOL    |
| 2   | 0.56        | [M - H] <sup>-</sup>                           | 154.0624     | 155.0695          | 1.2   | 137.0361 (C <sub>6</sub> H <sub>5</sub> N <sub>2</sub> O <sub>2</sub> ), 93.0449 (C <sub>3</sub> H <sub>5</sub> N <sub>2</sub> )   | C <sub>6</sub> H <sub>9</sub> N <sub>3</sub> O <sub>2</sub>  | Histidine   | MOL    |
| 3   | 0.59        | [M + HCOO] <sup>-</sup>                        | 264.1109     | 219.1107          | 0.6   | 146.0461 (C <sub>5</sub> H <sub>8</sub> NO <sub>4</sub> ), 114.0196 (C <sub>4</sub> H <sub>4</sub> NO <sub>3</sub> ), 88.0413 (C <sub>3</sub> H <sub>6</sub> NO <sub>2</sub> )   | C <sub>9</sub> H <sub>17</sub> NO <sub>5</sub>               | Pantothenic acid                                      | MOL    |
| 4   | 0.60        | [M - H] <sup>-</sup>                           | 146.0461     | 147.0532          | 1.8   | 102.0564 (C <sub>4</sub> H <sub>8</sub> NO <sub>2</sub> ), 88.0413 (C <sub>3</sub> H <sub>6</sub> NO <sub>2</sub> ), 74.0254 (C <sub>2</sub> H <sub>4</sub> NO <sub>2</sub> )    | C <sub>5</sub> H <sub>9</sub> NO <sub>4</sub>                | Gilitic acid  | MOL    |
| 5   | 0.60        | [M - H] <sup>-</sup>                           | 118.0512     | 119.0582          | 2     | 104.0358 (C <sub>3</sub> H <sub>6</sub> NO <sub>3</sub> ), 102.0564 (C <sub>4</sub> H <sub>8</sub> NO <sub>2</sub> ), 74.0254 (C <sub>2</sub> H <sub>4</sub> NO <sub>2</sub> )   | C <sub>4</sub> H <sub>9</sub> NO <sub>3</sub>                | Threonine   | MOL    |
| 6   | 0.60        | [M - H] <sup>-</sup>                           | 132.0305     | 133.0375          | 1.7   | 114.0196 (C <sub>4</sub> H <sub>4</sub> NO <sub>3</sub> ), 88.0404 (C <sub>3</sub> H <sub>6</sub> NO <sub>2</sub> ), 74.0248 (C <sub>2</sub> H <sub>4</sub> NO <sub>2</sub> )    | C <sub>4</sub> H <sub>7</sub> NO <sub>4</sub>                | Aspartic acid   | MOL    |
| 7   | 0.77        | [M - H] <sup>-</sup>                           | 191.0561     | 192.0634          | 0.1   | 119.0352 (C <sub>4</sub> H <sub>7</sub> O <sub>4</sub> ), 101.0252 (C <sub>4</sub> H <sub>5</sub> O <sub>3</sub> ), 95.0143 (C <sub>3</sub> H <sub>5</sub> O <sub>3</sub> )      | C <sub>7</sub> H <sub>12</sub> O <sub>6</sub>                | Quinic acid   | MOL    |
| 8   | 1.60        | [M + HCOO] <sup>-</sup>                        | 326.1248     | 281.1263          | 0.9   | 173.0449 (C <sub>10</sub> H <sub>7</sub> NO <sub>2</sub> ), 164.0706 (C <sub>9</sub> H <sub>10</sub> NO <sub>2</sub> ), 147.0454 (C <sub>9</sub> H <sub>7</sub> O <sub>2</sub> ) | C <sub>14</sub> H <sub>19</sub> NO <sub>5</sub>              | Tyrosine  | MOL    |
| 9   | 2.27        | [M - H] <sup>-</sup>                           | 353.0875     | 354.0951          | -0.8  | 179.0350 (C <sub>9</sub> H <sub>7</sub> O <sub>4</sub> ), 161.0244 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> ), 133.0293 (C <sub>8</sub> H <sub>5</sub> O <sub>2</sub> )     | C <sub>16</sub> H <sub>18</sub> O <sub>9</sub>               | 4-O-Caffeoylquinic acid                               | MOL    |
| 10  | 2.27        | [M - H] <sup>-</sup>                           | 179.0345     | 180.0423          | -2.7  | 161.0244 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> ), 133.0293 (C <sub>8</sub> H <sub>5</sub> O <sub>2</sub> )   | C <sub>9</sub> H <sub>8</sub> O <sub>4</sub>                 | Caffeic acid  | MOL    |
| 11  | 2.76        | [M - H] <sup>-</sup>                           | 163.0406     | 164.0473          | 3     | 119.0502 (C <sub>8</sub> H <sub>7</sub> O), 93.0346 (C <sub>6</sub> H <sub>5</sub> O)  | C <sub>9</sub> H <sub>8</sub> O <sub>3</sub>                 | <i>trans</i> -4-Hydroxycinnamic acid                  | MOL    |
| 12  | 2.93        | [M + Na] <sup>+</sup>                          | 543.1843     | 520.1945          | 1.2   | 423.1434 (C <sub>24</sub> H <sub>23</sub> O <sub>7</sub> ), 305.0985 (C <sub>16</sub> H <sub>17</sub> O <sub>6</sub> )   | C <sub>26</sub> H <sub>32</sub> O <sub>11</sub>              | (+)-Pi-nessinol-4-O-β-D-glucopyranoside               | MOL    |
| 13  | 2.96        | [M + HCOO] <sup>-</sup>                        | 375.0707     | 330.074           | -3.8  | 195.0299 (C <sub>9</sub> H <sub>7</sub> O <sub>5</sub> ), 179.0354 (C <sub>9</sub> H <sub>7</sub> O <sub>4</sub> ), 161.0242 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> )     | C <sub>17</sub> H <sub>14</sub> O <sub>7</sub>               | Cirsilol  | MOL    |
| 14  | 3.40        | [M + Na] <sup>+</sup>                          | 421.3462     | 398.3549          | 4.9   | 343.3362 (C <sub>23</sub> H <sub>43</sub> )  | C <sub>28</sub> H <sub>46</sub> O                            | 24-Methylenecholesterol                               | MOL    |
| 15  | 3.40        | [M - H] <sup>-</sup>                           | 593.1507     | 594.1585          | -0.9  | 473.1089 (C <sub>23</sub> H <sub>21</sub> O <sub>11</sub> ), 323.551 (C <sub>18</sub> H <sub>11</sub> O <sub>6</sub> ), 161.0237 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> ) | C <sub>27</sub> H <sub>30</sub> O <sub>15</sub>              | Vicenin 2   | MOL    |
| 16  | 4.31        | [M + HCOO] <sup>-</sup>                        | 324.1091     | 279.1107          | 0.6   | 132.0455 (C <sub>8</sub> H <sub>6</sub> NO), 89.0256 (C <sub>3</sub> H <sub>5</sub> O <sub>3</sub> )   | C <sub>14</sub> H <sub>17</sub> NO <sub>5</sub>              | Niazirin  | MOL    |
| 17  | 5.34        | [M - H] <sup>-</sup>                           | 609.1458     | 610.1534          | -0.6  | 300.0275 (C <sub>15</sub> H <sub>8</sub> O <sub>7</sub> ), 301.0336 (C <sub>15</sub> H <sub>6</sub> O <sub>7</sub> ), 151.0043 (C <sub>7</sub> H <sub>5</sub> O <sub>4</sub> )   | C <sub>27</sub> H <sub>30</sub> O <sub>16</sub>              | Rutin   | MOL    |
| 18  | 5.41        | [M - H] <sup>-</sup>                           | 431.0985     | 432.1057          | 0.3   | 323.0528 (C <sub>18</sub> H <sub>11</sub> O <sub>6</sub> ), 117.0345 (C <sub>8</sub> H <sub>5</sub> O)   | C <sub>21</sub> H <sub>20</sub> O <sub>10</sub>              | Cosmosiin   | MOL    |
| 19  | 5.77        | [M - H] <sup>-</sup>                           | 463.0881     | 464.0955          | -0.2  | 300.0275 (C <sub>15</sub> H <sub>8</sub> O <sub>7</sub> ), 243.0299 (C <sub>13</sub> H <sub>7</sub> O <sub>5</sub> ), 151.0041 (C <sub>7</sub> H <sub>5</sub> O <sub>4</sub> )   | C <sub>21</sub> H <sub>20</sub> O <sub>12</sub>              | Isoquercitrin   | MOL    |
| 20  | 6.95        | [M + HCOO] <sup>-</sup> , [M - H] <sup>-</sup> | 567.2081     | 522.2101          | 0     | 341.1402 (C <sub>20</sub> H <sub>21</sub> O <sub>5</sub> ), 311.0917 (C <sub>18</sub> H <sub>15</sub> O <sub>5</sub> )   | C <sub>26</sub> H <sub>34</sub> O <sub>11</sub>              | (+)-Isolaricresinol-3α-O-β-D-glucopyranoside          | MOL    |
| 21  | 6.49        | [M - H] <sup>-</sup>                           | 549.0877     | 550.0959          | -1.6  | 505.0968 (C <sub>23</sub> H <sub>21</sub> O <sub>13</sub> ), 300.0273 (C <sub>15</sub> H <sub>8</sub> O <sub>7</sub> ), 151.0416 (C <sub>8</sub> H <sub>7</sub> O <sub>3</sub> ) | C <sub>24</sub> H <sub>22</sub> O <sub>15</sub>              | Quercetin-3-O-(6-malondiy)-β-D-glucopyranoside        | MOL    |
| 22  | 11.61       | [M + Na] <sup>+</sup>                          | 491.3506     | 468.3604          | 2     | 412.3362 (C <sub>28</sub> H <sub>44</sub> O <sub>2</sub> ), 361.2872 (C <sub>27</sub> H <sub>37</sub> )  | C <sub>31</sub> H <sub>48</sub> O <sub>3</sub>               | 3β-Hydroxy-oleano-11,13 (18)-diene-28-carboxylic acid | MOL    |



Table 2 (Contd.)

| No. | $t_R$ (min) | Ion type                   | M/Z          |                   | Error | The total number of pieces (ppm)  | Formula              | Compound name  | Source |
|-----|-------------|----------------------------|--------------|-------------------|-------|---|----------------------|--|--------|
|     |             |                            | Actual value | Theoretical value |       |   |                      |  |        |
| 23  | 7.02        | $[M - H]^-$                | 447.0937     | 448.1006          | 0.9   | 284.0327 ( $C_{15}H_8O_6$ ), 113.0617 ( $C_6H_9O_2$ )                                       | $C_{21}H_{20}O_{11}$ | Quercitrin   | MOL    |
| 24  | 4.24        | $[M - H]^-$                | 447.0926     | 448.0998          | 0.9   | 327.0522 ( $C_{17}H_{14}O_7$ ), 297.0401 ( $C_{16}H_9O_6$ )                                 | $C_{21}H_{20}O_{11}$ | Astragaln  | MOL    |
| 25  | 8.09        | $[M + H]^+$                | 435.3604     | 412.3705          | 1.5   | 321.3120 ( $C_{22}H_{14}O$ ), 209.2257 ( $C_{15}H_{29}$ )                                   | $C_{29}H_{48}O$      | Stigmastanol   | MOL    |
| 26  | 8.09        | $[M - H]^-$                | 591.1352     | 592.1428          | -0.6  | 489.1038 ( $C_{23}H_{21}O_{12}$ ), 284.0328 ( $C_{15}H_8O_6$ ), 227.0350 ( $C_{13}H_7O_4$ ) | $C_{27}H_{28}O_{15}$ | Kaempferol-3-O-hydroxymethyl glutaryl hexanoside       | MOL    |
| 27  | 8.10        | $[M - H]^-$                | 533.0935     | 534.101           | -0.4  | 489.1039 ( $C_{23}H_{21}O_{12}$ ), 285.0412 ( $C_{15}H_9O_6$ )                              | $C_{24}H_{22}O_{14}$ | Kaempferol-3-O-malondiacetylhexanoside                 | MOL    |
| 28  | 8.90        | $[M + Na]^+$               | 631.1258     | 608.1377          | -1.9  | 325.0326 ( $C_{17}H_9O_7$ ), 243.0162 ( $C_9H_7O_8$ ), 201.0444 ( $C_8H_6O_6$ )             | $C_{27}H_{28}O_{16}$ | Quercetin - 3-O-hydroxymethyl glutaryl galactoside     | MOL    |
| 29  | 9.78        | $[M + Na]^+$               | 315.2331     | 314.2246          | 4     | 228.1527 ( $C_{16}H_{20}O$ ), 176.1186 ( $C_{12}H_{16}O$ )                                  | $C_{21}H_{30}O_2$    | Progesterone   | MOL    |
| 30  | 10.02       | $[M + H]^+$                | 543.221      | 520.2309          | 1.7   | 431.1679 ( $C_{23}H_{27}O_8$ ), 279.1438 ( $C_{12}H_{23}O_7$ )                              | $C_{27}H_{36}O_{10}$ | Laricresinol-9-O- $\beta$ -D-glucopyranoside           | MOL    |
| 31  | 10.09       | $[M + Na]^+$ , $[M + H]^+$ | 457.3696     | 456.3604          | 4.3   | 221.1942 ( $C_{15}H_{25}O$ ), 101.1337 ( $C_7H_{17}$ )                                      | $C_{30}H_{48}O_3$    | Oleanolic acid   | MOL    |
| 32  | 10.51       | $[M + HCOO]^-$             | 423.1663     | 378.1679          | 0.5   | 165.0194 ( $C_8H_5O_4$ ), 109.0293 ( $C_6H_5O_2$ )  | $C_{20}H_{26}O_7$    | 1-(4-Hydroxy-3-methoxyphenyl)-2-[4-(3-hydroxypropyl)-2 | MOL    |
| 33  | 11.70       | $[M + Na]^+$               | 453.3682     | 430.3811          | -4.6  | 245.1536 ( $C_{16}H_{21}O_2$ ), 227.2369 ( $C_{15}H_{31}O$ ), 209.2264 ( $C_{15}H_{29}$ )   | $C_{23}H_{50}O_2$    | Vitamin E  | MOL    |
| 34  | 0.60        | $[M - H]^-$                | 132.0298     | 133.037           | -3.63 | 115.0031 ( $C_4H_3O_4$ ), 88.0406 ( $C_3H_6NO_2$ ), 74.0252 ( $C_2H_4NO_2$ )                | $C_4H_7NO_4$         | Aspartic acid  | MOS    |
| 35  | 0.61        | $[M - H]^-$                | 146.0453     | 147.0526          | -3.66 | 102.0558 ( $C_4H_8NO_2$ ), 88.0406 ( $C_3H_6NO_2$ ), 74.0252 ( $C_2H_4NO_2$ )               | $C_5H_9NO_4$         | Glutamic acid  | MOS    |
| 36  | 0.90        | $[M + HCOO]^-$             | 150.0408     | 105.0426          | 0.23  | 87.0090 ( $C_3H_5O_3$ ), 59.0147 ( $C_2H_3O_2$ )  | $C_3H_7NO_3$         | Serine   | MOS    |
| 37  | 1.09        | $[M + H]^+$                | 147.1134     | 146.1062          | 4.29  | 135.1137 ( $C_{10}H_{15}$ ), 128.0944 ( $C_6H_{12}N_2O$ )                                   | $C_6H_{14}N_2O_2$    | Lysine   | MOS    |
| 38  | 1.25        | $[M + HCOO]^-$             | 326.1223     | 281.1263          | -6.92 | 164.0714 ( $C_9H_{10}NO_3$ ), 105.0345 ( $C_7H_5O$ )  | $C_{14}H_{19}NO_5$   | Tyrosine   | MOS    |
| 39  | 1.80        | $[M + HCOO]^-$             | 399.0948     | 354.0966          | 3.83  | 209.0442 ( $C_{10}H_6O_5$ ), 149.0237 ( $C_8H_5O_3$ ), 108.0213 ( $C_6H_4O_2$ )             | $C_{16}H_{18}O_9$    | 4-O-Caffeoyl-quinic acid                               | MOS    |
| 40  | 2.06        | $[M - H]^-$                | 218.1029     | 219.1102          | -2.22 | 146.0816 ( $C_6H_{12}NO_3$ ), 99.0450 ( $C_5H_7O_2$ )                                       | $C_9H_{17}NO_5$      | Pantothenic acid                                       | MOS    |
| 41  | 2.46        | $[M + H]^+$                | 521.2372     | 520.23            | -1.69 | 405.1908 ( $C_{22}H_{29}O_7$ ), 375.1834 ( $C_{21}H_{27}O_6$ )                              | $C_{27}H_{36}O_{10}$ | Laricresinol-9-O- $\beta$ -D-glucopyranoside           | MOS    |
| 42  | 2.82        | $[M - H]^-$                | 353.0867     | 354.094           | -3.2  | 184.0715 ( $C_9H_{12}O_4$ ), 143.0357 ( $C_8H_6O_2$ ), 23.0812 ( $C_{12}H_{14}O_3$ )        | $C_{16}H_{18}O_9$    | Chlorogenic acid                                       | MOS    |
| 43  | 2.83        | $[M + HCOO]^-$             | 579.0977     | 534.0995          | -2.55 | 169.0495 ( $C_8H_9O_4$ ), 143.0340 ( $C_6H_7O_4$ ), 95.0133 ( $C_5H_5O_2$ )                 | $C_{24}H_{22}O_{14}$ | Kaempferol-3-O-malondiacetylhexanoside                 | MOS    |
| 44  | 3.10        | $[M + HCOO]^-$             | 243.0502     | 198.052           | -3.48 |   | $C_9H_{10}O_5$       | Syringic acid  | MOS    |



Table 2 (Contd.)

| No. | $t_R$ (min) | Ion type                                    | M/Z          |                   | Error | The total number of pieces (ppm)  | Formula   | Compound name                                | Source |
|-----|-------------|---|--------------|-------------------|-------|---|---|--|--------|
|     |             |   | Actual value | Theoretical value |       |   |   |  |        |
| 45  | 3.22        | [M + HCOO] <sup>-</sup>                     | 389.0886     | 344.0904          | 2.15  | 164.0460 (C <sub>9</sub> H <sub>8</sub> O <sub>3</sub> ), 134.0370 (C <sub>8</sub> H <sub>6</sub> O <sub>2</sub> )  | C <sub>18</sub> H <sub>16</sub> O <sub>7</sub>                | Cirsilineol                                  | MOS    |
| 46  | 4.44        | [M + H] <sup>+</sup>                        | 595.1425     | 594.1352          | -3.58 | 193.0501 (C <sub>10</sub> H <sub>6</sub> O <sub>4</sub> ), 178.02724 (C <sub>9</sub> H <sub>6</sub> O <sub>4</sub> )  | C <sub>30</sub> H <sub>26</sub> O <sub>13</sub>               | Procyanidin                                  | MOS    |
| 47  | 4.46        | [M - H] <sup>-</sup>                        | 179.0345     | 180.0418          | -2.68 | 161.0238 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> ), 133.0295 (C <sub>8</sub> H <sub>5</sub> O <sub>2</sub> ), 109.0295 (C <sub>6</sub> H <sub>5</sub> O <sub>2</sub> )  | C <sub>9</sub> H <sub>8</sub> O <sub>4</sub>                  | Caffeic acid                                 | MOS    |
| 48  | 7.56        | [M + HCOO] <sup>-</sup>                     | 509.0961     | 464.0979          | 4.76  | 299.0196 (C <sub>13</sub> H <sub>6</sub> O <sub>7</sub> ), 243.0289 (C <sub>13</sub> H <sub>7</sub> O <sub>5</sub> ), 151.0025 (C <sub>7</sub> H <sub>3</sub> O <sub>4</sub> )  | C <sub>21</sub> H <sub>20</sub> O <sub>12</sub>               | Isoquercitrin                                | MOS    |
| 49  | 4.68        | [M + HCOO] <sup>-</sup>                     | 223.0242     | 178.026           | -2.86 | 125.0237 (C <sub>6</sub> H <sub>5</sub> O <sub>3</sub> ), 109.0290 (C <sub>6</sub> H <sub>5</sub> O <sub>2</sub> )  | C <sub>9</sub> H <sub>6</sub> O <sub>4</sub>                  | Esculetin                                    | MOS    |
| 50  | 7.13        | [M - H] <sup>-</sup> , [HCOO] <sup>-</sup>  | 609.1529     | 610.1534          | -0.86 | 300.0254 (C <sub>13</sub> H <sub>8</sub> O <sub>7</sub> ), 301.0339 (C <sub>13</sub> H <sub>9</sub> O <sub>7</sub> ), 167.0322 (C <sub>8</sub> H <sub>3</sub> O <sub>4</sub> )  | C <sub>27</sub> H <sub>30</sub> O <sub>16</sub>               | Rutin  | MOS    |
| 51  | 4.93        | [M - H] <sup>-</sup> , [HCOO] <sup>-</sup>  | 289.0715     | 290.0788          | -0.78 | 167.0711 (C <sub>9</sub> H <sub>11</sub> O <sub>3</sub> ), 137.0239 (C <sub>7</sub> H <sub>5</sub> O <sub>3</sub> ), 108.0214 (C <sub>6</sub> H <sub>4</sub> O <sub>2</sub> ), 179.0341 (C <sub>9</sub> H <sub>7</sub> O <sub>4</sub> ) | C <sub>15</sub> H <sub>14</sub> O <sub>6</sub>                | (-)-Epicatechin                              | MOS    |
| 52  | 5.57        | [M - H] <sup>-</sup>                        | 593.1505     | 594.1578          | -1.09 | 473.1081 (C <sub>23</sub> H <sub>21</sub> O <sub>11</sub> ), 323.0546 (C <sub>18</sub> H <sub>11</sub> O <sub>6</sub> ), 161.0235 (C <sub>9</sub> H <sub>5</sub> O <sub>3</sub> )   | C <sub>27</sub> H <sub>30</sub> O <sub>15</sub>               | Vicenin 2                                    | MOS    |
| 53  | 5.63        | [M + HCOO] <sup>-</sup> , [-H] <sup>-</sup> | 324.1087     | 279.1105          | -0.4  | 132.0450 (C <sub>8</sub> H <sub>6</sub> NO), 89.0247 (C <sub>3</sub> H <sub>5</sub> O <sub>3</sub> )  | C <sub>14</sub> H <sub>17</sub> NO <sub>5</sub>               | Niazirin                                     | MOS    |
| 54  | 5.64        | [M + Na] <sup>+</sup>                       | 464.1288     | 441.1395          | -0.29 | 185.0457 (C <sub>11</sub> H <sub>7</sub> NO <sub>2</sub> ), 171.0299 (C <sub>10</sub> H <sub>5</sub> NO <sub>2</sub> )  | C <sub>19</sub> H <sub>19</sub> N <sub>7</sub> O <sub>6</sub> | Folic acid                                   | MOS    |
| 55  | 5.70        | [M + HCOO] <sup>-</sup>                     | 361.0554     | 316.0572          | -2.94 | 165.0541 (C <sub>9</sub> H <sub>6</sub> O <sub>3</sub> ), 122.0367 (C <sub>7</sub> H <sub>6</sub> O <sub>2</sub> ), 145.0285 (C <sub>9</sub> H <sub>5</sub> O <sub>2</sub> )  | C <sub>16</sub> H <sub>12</sub> O <sub>7</sub>                | Isothamnetin                                 | MOS    |
| 56  | 5.92        | [M - H] <sup>-</sup>                        | 447.0914     | 448.0987          | -4.11 | 327.0495 (C <sub>17</sub> H <sub>11</sub> O <sub>7</sub> ), 297.0397 (C <sub>16</sub> H <sub>9</sub> O <sub>6</sub> )   | C <sub>21</sub> H <sub>20</sub> O <sub>11</sub>               | Astragalin                                   | MOS    |
| 57  | 5.98        | [M - H] <sup>-</sup>                        | 163.0393     | 164.0466          | -4.79 | 119.0500 (C <sub>8</sub> H <sub>7</sub> O), 117.0337 (C <sub>8</sub> H <sub>5</sub> O), 93.0351 (C <sub>6</sub> H <sub>5</sub> O)   | C <sub>9</sub> H <sub>8</sub> O <sub>3</sub>                  | <i>trans</i> -Cinnamic acid                  | MOS    |
| 58  | 6.66        | [M + HCOO] <sup>-</sup>                     | 539.1219     | 494.1237          | 4.48  | 179.0340 (C <sub>9</sub> H <sub>7</sub> O <sub>4</sub> ), 151.0389 (C <sub>8</sub> H <sub>7</sub> O <sub>3</sub> ), 135.0448 (C <sub>8</sub> H <sub>7</sub> O <sub>2</sub> )  | C <sub>26</sub> H <sub>22</sub> O <sub>10</sub>               | Salvianolic acid A                           | MOS    |
| 59  | 6.72        | [M - H] <sup>-</sup>                        | 475.0904     | 476.0976          | 4.56  | 304.0604 (C <sub>15</sub> H <sub>12</sub> O <sub>7</sub> ), 286.0494 (C <sub>15</sub> H <sub>10</sub> O <sub>6</sub> ), 125.0244 (C <sub>6</sub> H <sub>5</sub> O <sub>3</sub> )  | C <sub>22</sub> H <sub>20</sub> O <sub>12</sub>               | Kaempferol-3-O-(6''-acetyl glucoside)        | MOS    |
| 60  | 6.80        | [M - H] <sup>-</sup>                        | 193.0497     | 194.057           | -4.82 | 180.0417 (C <sub>9</sub> H <sub>8</sub> O <sub>4</sub> ), 133.0285 (C <sub>8</sub> H <sub>5</sub> O <sub>2</sub> ), 108.0221 (C <sub>6</sub> H <sub>4</sub> O <sub>2</sub> )  | C <sub>10</sub> H <sub>10</sub> O <sub>4</sub>                | Ferulic acid                                 | MOS    |
| 61  | 7.01        | [M + H] <sup>+</sup>                        | 743.2399     | 742.2327          | 0.87  | 473.1683 (C <sub>21</sub> H <sub>29</sub> O <sub>12</sub> ), 397.1092 (C <sub>18</sub> H <sub>21</sub> O <sub>10</sub> ), 313.0964 (C <sub>14</sub> H <sub>17</sub> O <sub>8</sub> )  | C <sub>33</sub> H <sub>42</sub> O <sub>19</sub>               | Troloxerutin                                 | MOS    |
| 62  | 7.07        | [M - H] <sup>-</sup>                        | 317.1028     | 318.11            | -0.97 | 255.0651 (C <sub>15</sub> H <sub>11</sub> O <sub>4</sub> ), 135.0081 (C <sub>7</sub> H <sub>5</sub> O <sub>3</sub> ), 108.0214 (C <sub>6</sub> H <sub>4</sub> O <sub>2</sub> )  | C <sub>17</sub> H <sub>18</sub> O <sub>6</sub>                | Evofolin B                                   | MOS    |
| 63  | 6.52        | [M + HCOO] <sup>-</sup>                     | 567.2052     | 522.2101          | -2.05 | 451.1628 (C <sub>22</sub> H <sub>27</sub> O <sub>10</sub> ), 311.0917 (C <sub>18</sub> H <sub>15</sub> O <sub>5</sub> )   | C <sub>26</sub> H <sub>34</sub> O <sub>11</sub>               | (+)-Isolonicresinol-3a-O-β-D-glucopyranoside | MOS    |
| 64  | 7.20        | [M - H] <sup>-</sup>                        | 431.0983     | 432.1055          | -0.27 | 323.0555 (C <sub>18</sub> H <sub>11</sub> O <sub>6</sub> ), 117.0343 (C <sub>8</sub> H <sub>5</sub> O)  | C <sub>21</sub> H <sub>20</sub> O <sub>10</sub>               | Cosmosiin                                    | MOS    |



Table 2 (Contd.)

| No. | $t_R$ (min) | Ion type                                   | M/Z          |                   | Error | The total number of pieces (ppm)   | Formula   | Compound name  | Source |
|-----|-------------|--|--------------|-------------------|-------|--|---|--|--------|
|     |             |  | Actual value | Theoretical value |       |  |   |  |        |
| 65  | 7.20        | [M - H] <sup>-</sup>                       | 431.0983     | 432.1055          | -0.27 | 253.0492 (C <sub>15</sub> H <sub>9</sub> O <sub>4</sub> ), 145.0273 (C <sub>9</sub> H <sub>5</sub> O <sub>2</sub> ), 93.0347 (C <sub>6</sub> H <sub>5</sub> O)                     | C <sub>21</sub> H <sub>20</sub> O <sub>10</sub> | Isovitexin   | MOS    |
| 66  | 7.20        | [M - H] <sup>-</sup>                       | 283.0606     | 284.0679          | -2.17 | 151.0029 (C <sub>7</sub> H <sub>5</sub> O <sub>4</sub> ), 145.0273 (C <sub>9</sub> H <sub>5</sub> O <sub>2</sub> ), 117.0343 (C <sub>8</sub> H <sub>5</sub> O)                     | C <sub>16</sub> H <sub>12</sub> O <sub>5</sub>  | Acacetin   | MOS    |
| 67  | 7.38        | [M - H] <sup>-</sup>                       | 285.0395     | 286.0468          | -3.42 | 152.0113 (C <sub>7</sub> H <sub>4</sub> O <sub>4</sub> ), 125.0239 (C <sub>6</sub> H <sub>5</sub> O <sub>3</sub> ), 108.0214 (C <sub>6</sub> H <sub>4</sub> O <sub>2</sub> )       | C <sub>15</sub> H <sub>10</sub> O <sub>6</sub>  | Luteolin   | MOS    |
| 68  | 8.37        | [M - H] <sup>-</sup>                       | 549.0867     | 550.0939          | -3.53 | 505.0974 (C <sub>23</sub> H <sub>21</sub> O <sub>13</sub> ), 300.0269 (C <sub>13</sub> H <sub>8</sub> O <sub>7</sub> ), 151.0391 (C <sub>8</sub> H <sub>7</sub> O <sub>3</sub> )   | C <sub>24</sub> H <sub>22</sub> O <sub>15</sub> | Quercetin-3-O-(6-malondiy)-β-D-glucopyranoside       | MOS    |
| 69  | 8.89        | [M - H] <sup>-</sup>                       | 447.0919     | 448.0992          | -3.14 | 284.0316 (C <sub>13</sub> H <sub>8</sub> O <sub>6</sub> ), 93.0349 (C <sub>6</sub> H <sub>5</sub> O)   | C <sub>21</sub> H <sub>20</sub> O <sub>11</sub> | Quercitrin   | MOS    |
| 70  | 9.57        | [M + HCOO] <sup>-</sup>                    | 317.0657     | 272.0675          | -3.16 | 162.0296 (C <sub>9</sub> H <sub>6</sub> O <sub>3</sub> ), 147.0431 (C <sub>9</sub> H <sub>7</sub> O <sub>2</sub> )   | C <sub>15</sub> H <sub>12</sub> O <sub>5</sub>  | Naringenin   | MOS    |
| 71  | 9.93        | [M + HCOO] <sup>-</sup>                    | 359.0756     | 314.0774          | -4.64 | 283.0592 (C <sub>16</sub> H <sub>11</sub> O <sub>5</sub> ), 178.0256 (C <sub>9</sub> H <sub>6</sub> O <sub>4</sub> )   | C <sub>17</sub> H <sub>14</sub> O <sub>6</sub>  | Cirsimaritin   | MOS    |
| 72  | 10.03       | [M - H] <sup>-</sup>                       | 591.1343     | 592.1416          | -2.07 | 489.1033 (C <sub>23</sub> H <sub>21</sub> O <sub>12</sub> ), 284.0312 (C <sub>15</sub> H <sub>8</sub> O <sub>6</sub> ), 227.0343 (C <sub>13</sub> H <sub>7</sub> O <sub>4</sub> )  | C <sub>27</sub> H <sub>28</sub> O <sub>15</sub> | Kaempferol-3-O-hydroxymethyl glutaryl hexanoside     | MOS    |
| 73  | 10.36       | [M + HCOO] <sup>-</sup>                    | 433.1487     | 388.1505          | -4.04 | 373.1269 (C <sub>20</sub> H <sub>21</sub> O <sub>7</sub> ), 341.1032 (C <sub>19</sub> H <sub>17</sub> O <sub>6</sub> ), 181.0484 (C <sub>9</sub> H <sub>9</sub> O <sub>4</sub> )   | C <sub>21</sub> H <sub>24</sub> O <sub>7</sub>  | Medioresinol   | MOS    |
| 74  | 11.01       | [M - H] <sup>-</sup> , [HCOO] <sup>-</sup> | 359.1482     | 360.1555          | -4.91 | 329.1376 (C <sub>19</sub> H <sub>21</sub> O <sub>5</sub> ), 314.1159 (C <sub>18</sub> H <sub>18</sub> O <sub>5</sub> ), 180.0777 (C <sub>10</sub> H <sub>12</sub> O <sub>3</sub> ) | C <sub>20</sub> H <sub>24</sub> O <sub>6</sub>  | (7S,8R)-Dihydrodehydrodiguaiacyl alcohol             | MOS    |
| 75  | 12.57       | [M + H] <sup>+</sup>                       | 719.1617     | 718.1544          | 1.38  | 535.1587 (C <sub>23</sub> H <sub>27</sub> O <sub>10</sub> ), 193.0839 (C <sub>22</sub> H <sub>13</sub> O <sub>3</sub> ), 149.0585 (C <sub>9</sub> H <sub>9</sub> O <sub>2</sub> )  | C <sub>36</sub> H <sub>30</sub> O <sub>16</sub> | Salvianolic acid B                                   | MOS    |
| 76  | 13.14       | [M + Na] <sup>+</sup>                      | 553.1343     | 530.1451          | 4.86  | 396.10618 (C <sub>18</sub> H <sub>20</sub> O <sub>10</sub> ), 237.1079 (C <sub>13</sub> H <sub>17</sub> O <sub>4</sub> )   | C <sub>26</sub> H <sub>26</sub> O <sub>12</sub> | 3,4-Di-O-caffeoylquinic                              | MOS    |
| 77  | 13.40       | [M + Na] <sup>+</sup>                      | 543.184      | 520.1949          | 0.88  | 421.1275 (C <sub>24</sub> H <sub>21</sub> O <sub>7</sub> ), 340.1154 (C <sub>16</sub> H <sub>20</sub> O <sub>8</sub> )   | C <sub>28</sub> H <sub>32</sub> O <sub>11</sub> | (+)-Pi-noresinol-4-O-β-D-glucopyranoside             | MOS    |
| 78  | 13.74       | [M + H] <sup>+</sup>                       | 469.3669     | 468.3596          | -1.62 | 413.3384 (C <sub>28</sub> H <sub>45</sub> O <sub>2</sub> ), 361.28765 (C <sub>27</sub> H <sub>37</sub> )   | C <sub>31</sub> H <sub>48</sub> O <sub>3</sub>  | 3β-Hydroxy-oleano-11,13(18)-diene-28-carboxylic acid | MOS    |



Table 3 Health benefits of *M. oleifera*

| Effect                                   | Disease                                    | Subjects                                  | Model           | Dose  | Components  | Mechanism of action  | Functional properties   | Ref. |
|--|--|---|-----------------|---|---|--|---|------|
| Antioxidant and anti-inflammatory effect | Paw edema and peritonitis                  | Female Swiss ( <i>Mus musculus</i> ) mice | <i>In vivo</i>  | 15 mg kg <sup>-1</sup> , 30 mg kg <sup>-1</sup>   | <i>M. oleifera</i> flowers trypsin inhibitor (MoFTI)                        | Reduced leukocyte migration, plasma extravasation (attributed to lower protein content), and the levels of NO and pro-inflammatory (tumor necrosis factor- $\alpha$ , interleukin IL-6, and IL-17A) and anti-inflammatory (IL-4 and IL-10) cytokines | Promote anti-inflammatory activity  | 60   |
| —  | —  | Chang liver cells                         | <i>In vitro</i> | 2 mg mL <sup>-1</sup> , 4 mg mL <sup>-1</sup> , 6 mg mL <sup>-1</sup> , 250 mg mL <sup>-1</sup> | <i>M. oleifera</i> seeds protein hydrolysate (FM3)                          | Increasing the activities of endogenous antioxidant enzymes SOD and CAT, and scavenging intracellular ROS  | Protect hepatocytes from oxidative stress damage. May be used as potential antioxidants or protective agents against oxidative damage to cells  | 61   |
| Diabetic nephropathy                     | HRMC cell, Sprague Dawley rats             | <i>In vitro, in vivo</i>                  |                 | 200 mg kg <sup>-1</sup>   | <i>M. oleifera</i> seeds extract (MOS)                                      | Antioxidant and anti-renal fibrosis activities by increasing the activity of GSK-3 $\beta$ and the expression of Nrf2 and HO-1   | Delay the progression of diabetic nephropathy by improving renal function and reducing patho-physiological changes  | 62   |
| Male reproductive system health          | Wistar male rats                           | <i>in vivo</i>                            |                 | 0.55 mg kg <sup>-1</sup> , 1.10 mg kg <sup>-1</sup> and 2.20 mg kg <sup>-1</sup>                | <i>M. oleifera</i> leaves tea (total phenols, flavonoids, and antioxidants) | Increase sertoli cells and the total spermatogenic cells; scavenged DPPH radical, APTS radical and H <sub>2</sub> O <sub>2</sub> , and inhibit the formation of LPO and AGEs   | Rich total phenols, flavonoids, and antioxidants could enhance sexual function and the male reproductive system. Increased the courtship behavior, seminiferous tubule diameter, epithelium height, epithelium area, type A spermatogonia, and spermatogonia efficiency | 32   |
| Rat paw edema                            | RAW 264.7 murine cell, Sprague Dawley rats | <i>In vitro, in vivo</i>                  |                 | 1 $\mu$ M, 5 $\mu$ M, 33 mg kg <sup>-1</sup>  | <i>M. oleifera</i> seed extract (MSE)                                       | MIC-1 decreased inflammatory signaling (NO production, gene expression of iNOS, IL-1 $\beta$ , IL-6) and promoted detoxification (gene expression of NQO1, HO1, GSTP1) in LPS-stimulated murine macrophages  | Anti-inflammatory and antioxidant properties <i>in vivo</i> and <i>in vitro</i>   | 63   |



Table 3 (Contd.)

| Effect                                   | Disease                            | Subjects  | Model                    | Dose  | Components   | Mechanism of action  | Functional properties  | Ref. |
|--|------------------------------------|---|--------------------------|---|--|--|--|------|
|  | —                                  | Murine macrophage cell line RAW 246.7   | <i>In vitro</i>          | 50 $\mu\text{g mL}^{-1}$ , 100 $\mu\text{g mL}^{-1}$  | <i>M. oleifera</i> leaves protein hydrolysate (MOPH) | Peptides remove DDPH and ABTS radicals and exhibit strong ORAC determination activity. Increase in the number of exposed amino acid residues and promote an increase in scavenging activity; inhibits NO production and acts as an anti-inflammatory   | Antioxidant and anti-inflammatory activity   | 56   |
| Antioxidant and anti-inflammatory effect | Hepatic inflammation               | Healthy adult male mice   | <i>In vivo</i>           | 100 $\text{mg kg}^{-1}$ , 200 $\text{mg kg}^{-1}$ , 400 $\text{mg kg}^{-1}$   | <i>M. oleifera</i> leaves extract (MOLE)             | Modulated TLR4/NF- $\kappa$ B pathway, suppressed TLR4 and NF- $\kappa$ B gene expression and as well as TLR4 and NF- $\kappa$ B-p65 protein expression. Protects from apoptotic cell death <i>via</i> antioxidative and anti-inflammatory impacts with consequent attenuation of DNA-induced genotoxicity | Protective role against hepatotoxicity   | 64   |
|  | Ageing                             | Wistar albino rats  | <i>In vivo</i>           | 200 $\text{mg per kg per body weight}$  | <i>M. oleifera</i> leaves (MOAE)                     | Reduced lipid peroxidation and lipofuscin pigmentation increased serotonin and antioxidant enzymes   | Protective effect on age-related cerebral oxidative stress                             | 65   |
|  | Stomach and forestomach ulceration | <i>E. coli</i> , <i>P. aeruginosa</i> , <i>S. aureus</i> , Sprague-Dawley male rats | <i>In vivo, in vitro</i> | 100–500 $\mu\text{g mL}^{-1}$ , 100 $\text{mg kg}^{-1}$   | <i>M. oleifera</i> leaves extract                    | Hydrochloric acid secretion neutralization effect in gastric mucosa, decreased MDA level and increasing antioxidant enzyme activity (CAT, SOD, GPx)  | Anti-ulcer effect, protect the gastric ulcer   | 66   |
|  |                                    | Wistar albino male rats   | <i>In vivo</i>           | 200 $\text{mg per kg body wt}$  | <i>M. oleifera</i> aqueous extract                   | Reduces oxidative stress-induced DNA damage by improving NF- $\kappa$ B and TNF- $\alpha$ , restoring lead disturbance, preserving hepatocyte integrity and reducing serum liver enzyme activity   | Alleviated lead-induced adverse effects  | 67   |
| Antitumor effect                         | Human breast cancer cells          | Breast cancer cells, T-47D and MDA-MB-231   | <i>in vitro</i>          | 0.25 $\mu\text{g mL}^{-1}$ , 5 $\mu\text{g mL}^{-1}$ , 10 $\mu\text{g mL}^{-1}$ , 15 $\mu\text{g mL}^{-1}$ , 20 $\mu\text{g mL}^{-1}$ , 40 $\mu\text{g mL}^{-1}$ , 80 $\mu\text{g mL}^{-1}$ , 100 $\mu\text{g mL}^{-1}$ | <i>M. oleifera</i> leaves methanolic extract (MOME)  | Antiproliferative effect on T-47D and MDA-MB-231. The phosphatidylserine exposure on the membrane of the cells confirmed the mitochondria mediated intrinsic apoptosis induction in the MOME treated cells   | Contributes to cell cycle arrest and inhibits the proliferation of breast cancer cells | 68   |



Table 3 (Contd.)

| Effect           | Disease                                    | Subjects   | Model                    | Dose   | Components  | Mechanism of action  | Functional properties  | Ref. |
|------------------|--|--|--------------------------|--|---|--|--|------|
| Antitumor effect | MDA-MB-231 cells                           | MDA-MB-231 cells, Female mice                        | <i>In vitro, in vivo</i> | A high-fat diet (HFD) supplemented with 0.6% w/w MC                | <i>M. oleifera</i> seeds concentrate (MC)               | Decreased fasting blood glucose and increased insulin sensitivity in mice after obesity attack. Decreased protein expression of CD31   | Protected against high-fat diet- and chemotherapy-induced increases in fasting glucose and improved insulin sensitivity                                    | 69   |
|                  | A549 lung and SNO oesophageal cancer       | A549 lung and SNO oesophageal cancer cells           | <i>In vitro</i>          | 1.575–393.83 $\mu\text{g mL}^{-1}$                                 | AuNP synthesized from MO aqueous leaf extracts (MLAuNP) | Increased caspase activity in SNO cells and PS externalization, $\Delta\Psi_m$ , caspase-9, caspase-3/7 activities, and decreased ATP levels in A549 cells. Increased, p53 mRNA and protein levels, SRp30a ( $P = 0.428$ ), Bax, Smac/DIABLO and PARP-1 24 kDa fragment levels and protein levels and activated alternate splicing with caspase-9a splice variant. Decreased Bcl-2, Hsp70, Skp2, Fbw7a, c-myc Mrna | No cytotoxic to PBMCs, pro-apoptotic properties were confirmed in A549 and SNO cells   | 70   |
|                  | The human pancreatic epithelioid carcinoma | PANC-1 cell, immune deficient athymic CD-1 nude mice | <i>In vivo</i>           | 0.5, 1.0, and 1.5 $\text{mg g}^{-1}$ , 200 $\mu\text{L}$ per mouse | <i>M. oleifera</i> aqueous leaves extract               | Induction of apoptosis. Decreased expression of the pro-apoptotic protein Bcl-2, and downregulated the key component of DNA repair pathways PARP-1 and the NF- $\kappa\text{B}$ -related proteins I $\kappa\text{B}$ - $\alpha$ , p65-subunit, and COX-2   | Antiproliferative and antiangiogenic effects, decreased pancreatic cancer cell survival and metastatic activity and inhibited tumor growth                 | 71   |
|                  | Colorectal cancer                          | CD-1 male (ICR) mice                                 | <i>In vivo</i>           | 2.5% w/w and 5% w/w  | <i>M. oleifera</i> leaves powder                        | Reduce the activity of harmful faecal enzymes ( $\beta$ -glucosidase, $\beta$ -glucuronidase, tryptophanase and urease)  | Diminish colonic lesions and decrease the activity of fecal harmful enzymes such as $\beta$ -glucosidase, $\beta$ -glucuronidase, tryptophanase and urease | 72   |
|                  | Hepatocellular carcinoma                   | Wistar male rats                                     | <i>In vivo</i>           | 500 $\text{mg kg}^{-1}$  | <i>M. oleifera</i> leaf ethanol extract (MOLEE)         | Reduce Bcl-2 and Bcl-xL and the up-regulation of Bax and caspase 3, and reduced the expression level of $\beta$ -arrestin-2 mRNA, thus promoting apoptosis signal transduction   | Against DEN-induced HCC by exerting antioxidant and apoptotic activities   | 73   |





Table 3 (Contd.)

| Effect   | Disease             | Subjects                             | Model                    | Dose   | Components  | Mechanism of action  | Functional properties  | Ref. |
|--|---------------------|--------------------------------------|--------------------------|--|---|--|--|------|
|  | Sarcoma             | Sarcoma 180 cells, Swiss female mice | <i>In vitro, in vivo</i> | 24.6–25 $\mu\text{g mL}^{-1}$ , 15 or 30 $\text{mg kg}^{-1}$ | <i>M. oleifera</i> flower trypsin inhibitor (MoFTI) | Upregulation of pro-apoptotic proteins and the downregulation of anti-apoptotic proteins (e.g., Bcl-2 and Bcl-xl), caspase activation, and cytochrome c release. Induce ROS production and DNA fragmentation, suppress extracellular-signal-regulated kinase (ERK) activity, disrupt the cell cycle, and cause mitochondrial membrane damage | Cytotoxic to sarcoma 180 cells, reduce in tumor weight and antiangiogenic effect   | 74   |
| Gut protective and regulation of intestinal flora effect | Hymenolepiasis nana | Female Swiss albino mice             | <i>In vivo</i>           | 400 $\text{mg per kg body weight}$                           | <i>M. oleifera</i> leaves extract                   | Decreased TGF- $\beta$ , IFN- $\gamma$ and MMC counts <i>versus</i> increased GC counts, T-helper cell type 2 (Th2) cytokines and IgA level achieve protection against <i>H. nana</i> infections   | Anti-inflammatory and induce protection against <i>H. nana</i> infection   | 75   |
|  | Adiposity           | C57BL/6J male mice                   | <i>In vivo</i>           | Dietary supplementation with 0.34%MIC-1 (0.73%MSE)           | <i>M. oleifera</i> seed extract (MSE)               | Activate Nrf2 and its downstream targets and/or regulation of gut microbiota, MSE activates Nrf2 and its downstream targets and/or modulates the gut microbiota. MIC-1 has antibiotic properties, making it an, affecting host metabolism by regulating energy balance, glucose metabolism, lipid metabolism, and inflammation               | Reduce body weight, obesity and inflammatory gene expression, improve glucose tolerance, and increase antioxidant gene expression  | 46   |
|  | —                   | C57BL/6 mice                         | <i>In vivo</i>           | 40 $\text{mg kg}^{-1}$ , 60 $\text{mg kg}^{-1}$              | <i>M. oleifera</i> polysaccharides                  | Inhibit the expression levels of IL-6 and TNF- $\alpha$ , affecting immune repertoire and change immune state  | Regulate the intestinal flora, increase the relative abundance of beneficial bacteria and reduce the relative abundance of harmful bacteria, promoting intestinal health | 54   |



Table 3 (Contd.)

| Effect                        | Disease                              | Subjects                                | Model           | Dose  | Components  | Mechanism of action   | Functional properties   | Ref. |
|-------------------------------|--------------------------------------|---|-----------------|---|---|---|---|------|
|                               | —                                    | C57BL/7 mice                            | <i>In vivo</i>  | 20 mg kg <sup>-1</sup> , 40 mg kg <sup>-1</sup> , 61 mg kg <sup>-1</sup>                            | <i>M. oleifera</i> polysaccharides  | Reduced glucose, total cholesterol, and malondialdehyde. Improved superoxide dismutase and catalase in serum. Modulates the microbiological balance of the gut by increasing the abundance of good bacteria and decreasing the abundance of bad bacteria in the gut | Improve serum index, intestinal morphology, caecal microflora in mice and the villi length and crypt depth in both ileum and jejunum; increased the ratio of villi length to crypt depth in jejunum. Affecting the function of microbiota | 52   |
|                               | —                                    | Stool samples from healthy participants | <i>In vitro</i> | The stool suspension was loaded into sterile anaerobic jars containing 50 mg polysaccharide samples | <i>M. oleifera</i> root polysaccharides (MRP)                               | Improve the intestinal environment by producing short-chain fatty acids by intestinal flora fermentation, and maintain intestinal homeostasis by controlling the composition of intestinal flora  | Increased the content of beneficial microflora and decrease the abundance of harmful microflora   | 76   |
| Neuroprotective effect        | Glutamate-induced DNA damage in RGCs | RGCs cells                              | <i>In vitro</i> | 10 µg mL <sup>-1</sup> , 50 µg mL <sup>-1</sup> , 45 µg mL <sup>-1</sup>                            | <i>M. oleifera</i> seeds extract  | Increase neuronal cell viability and minimal cellular injury, extend branches in neurons, modulate axonal development, and promote synaptogenesis   | Neuroprotective effects   | 77   |
| Neuroprotective effect        | Neurodegenerative                    | Periodontal tissue cell                 | <i>In vitro</i> | 0.5 µM  | Moringin was isolated from <i>M. oleifera</i> seeds                         | Increased the expression of genes involved in neuron cortical development and in particular in neuron belonging to upper and deep cortical layers, involved in osteogenesis and adipogenesis  | Promote and accelerate cortical neuronal differentiation of hPDLSCs to improve stem cell therapy for neurological diseases  | 78   |
|                               | —                                    | PC12 cells                              | <i>In vitro</i> | 0.01 µM, 0.1 µM, 1 µM, 10 µM, 50 µM, and 100 µM   | Pyrrrole-2-carbaldehydes from <i>M. oleifera</i> seeds (pyrrolemorines A–G) | Against oxygen-glucose deprivation/reperfusion injury in PC12 cells by regulating NF-κb and Nrf2  | Pyrrrolemorines A, E, and pyrrolemarumine displayed neuroprotective activities, and attenuate PC12 cell damage induced by oxygen glucose deprivation  | 79   |
| Peripheral nerve injury (PNI) | Peripheral nerve injury (PNI)        | Adult male albino mice (BALB/c)         | <i>In vivo</i>  | 200 mg per kg body weight   | <i>M. oleifera</i> leaves extract   | Promoting effects of <i>M. oleifera</i> might be attributed to the flavonoid class  | Prove a valuable target for the discovery of effective and affordable intervention against peripheral nerve injuries  | 80   |



Table 3 (Contd.)

| Effect                               | Disease            | Subjects   | Model                     | Dose  | Components   | Mechanism of action  | Functional properties  | Ref. |
|--------------------------------------|--------------------|--|---------------------------|---|--|--|--|------|
| Ameliorate metabolic syndrome effect | NAFLD              | ICR mice, L02 cells  | <i>In vitro, in vitro</i> | 50 mg kg <sup>-1</sup> , 100 mg kg <sup>-1</sup> , and 200 mg kg <sup>-1</sup> , 0.2, 0.4, 0.6, 0.8, and 1 mM | <i>M. oleifera</i> seed extract containing 1-O-(4-hydroxy-methylphenyl)- $\alpha$ -L-rhamnopyranoside (GR) | Inhibits lipid accumulation in L1 cells by regulating AMPK/mTOR/SREBP-02 and PPAR $\alpha$ pathways. GR anti-inflammatory can promote PPAR $\alpha$ and AMPK, inhibiting downstream mTOR/SREBP-1, activating lipoprotein lipase and changing gene coding enzyme to induce transcription and participate in lipid and lipoprotein metabolism, improve the release of intracellular reactive oxygen species, reduce the accumulation of oil and TG, and promote lipid metabolism | Decreased serum fat content, inhibited liver injury, and increased antioxidant mechanism             | 81   |
|                                      | Diabetes           | Wistar male rats   | <i>In vivo</i>            | 500 mg kg <sup>-1</sup> , 250 mg kg <sup>-1</sup> and 500 mg kg <sup>-1</sup>                                 | <i>M. oleifera</i> leaves methanolic leave extracts (MO)   | Reduced inflammation and oxidative stress, reducing hyperglycemia-related liver damage   | Reduced fasting plasma ALAT, ASAT, GGT, albumin, and restored the damage hepatocellular architecture | 82   |
|                                      | Diabetes           | Pre-diabetic subjects aged 40 to 70 years who have not used medication to control glycemic | <i>In vivo</i>            | 1600 mg per day   | <i>M. oleifera</i> leaves capsule  | TNF- $\alpha$ to be a key factor to identify potential respondents   | The beneficial effect on blood glucose control in pre-diabetic patients                              | 83   |
| Ameliorate metabolic syndrome effect | Diabetes and NAFLD | C57BL/6 mice   | <i>In vivo</i>            | 250 mg kg <sup>-1</sup>   | <i>M. oleifera</i> fermentation extract (FM)   | Reduced high fat diet-induced ER stress, oxidative stress, lipid toxicity of quadriceps muscle and proinflammatory cytokine mRNA expression in the liver, epididymal adipose tissue, and quadriceps of HFD-fed mice, glucose intolerance and NAFLD in HFD-induced obesity by reducing ER stress, oxidative stress, and inflammation  | Antidiabetic effects and can be an effective dietary supplement for treating hyperglycemia and NAFLD | 84   |



Table 3 (Contd.)

| Effect | Disease                 | Subjects                       | Model          | Dose   | Components                            | Mechanism of action  | Functional properties   | Ref. |
|--------|-------------------------|--------------------------------|----------------|--|---------------------------------------|--|---|------|
|        | T2DM                    | UCD T2DM rats                  | <i>In vivo</i> | 202 mg per kg per day, 94 mg per kg per day                            | <i>M. oleifera</i> seeds extract      | Reduced inflammatory markers (KC/GRO and TNF- $\alpha$ ). MS has anti-inflammatory activity by activating Nrf2 pathway   | Delayed onset of diabetes in rat models of ucd T2DM   | 85   |
|        | Hypertensive            | Wistar Kyoto male rats         | <i>In vivo</i> | 750 mg per day per rat   | <i>M. oleifera</i> (MOI) seed powder  | Decreased the level of free 8-isoprostaglandin circulation and the expressions of iNOS and NF- $\kappa$ B protein were decreased, up-regulated the expressions of p <sup>22</sup> p <sup>phox</sup> and p <sup>47</sup> p <sup>phox</sup> and SOD2 | Vascular antioxidant, anti-inflammatory, and endothelial protective effects in SHR. Combat cardiovascular diseases associated with oxidative stress and inflammation  | 86   |
| Other  | Reproductive protection | NIH Swiss female and male mice | <i>In vivo</i> | Diet supplemented with 4% MOL, diet supplemented with 8% MOL           | <i>M. oleifera</i> leave (MOL) powder | Decreased serum MDA in both male and female mice, reduced the rate of sperm abnormality in male, and the expression of Bax   | Affecting reproductive  | 87   |
|        | —                       | NZW rabbits                    | <i>In vivo</i> | 5 g kg <sup>-1</sup> , 10 g kg <sup>-1</sup> and 15 g kg <sup>-1</sup> | <i>M. oleifera</i> leaves extract     | Attenuate phytoestrogen pituitary-gonadal axis, and reduced serum gonadotropin (FSH and LH) and oestrogen concentration in does  | Female rabbits: reductions in serum FSH, LH, and estrogen concentrations. Male rabbits: increased, FSH and LH, and decreased the serum testosterone concentration. Improved semen volume, sperm count and motility were significantly | 88   |
|        | —                       | Sprague Dawley male rats       | <i>In vivo</i> | 800 mg kg <sup>-1</sup>  | <i>M. oleifera</i> aqueous extract    | Reduces the oxidative stress in a unilateral cryptorchidism induced rats, and attenuate histopathological damages, HSP expression and germ cell apoptosis  | Increased apoptotic cells in the undescended testes. Decreased pathological damages, oxidative stress, expression level of HSP70 and apoptosis  | 20   |

Table 3 (Contd.)

| Effect | Disease               | Subjects  | Model | Dose  | Components                         | Mechanism of action  | Functional properties   | Ref. |
|--------|-----------------------|---|-------|---|------------------------------------|--|---|------|
| Other  | Promote wound healing | <i>P. aeruginosa</i> , <i>S. aureus</i> , and <i>E. coli</i> , Swiss albino male mice |       | <i>In vivo</i> , in hydrogel was formulated using 10 g of <i>M. oleifera</i> hexane seed extract and 90 g of gel  | <i>M. oleifera</i> seeds extract   | Antioxidant, antimicrobial, and wound healing activities. Gram-positive and Gram-negative bactericidal potential   | Could be used as potential herbal wound healing agents                                      | 89   |
|        | Diabetic foot ulcers  | Wistar male rats  |       | <i>In vivo</i> 0.5%, 1%, and 2% w/w aqueous fraction  | <i>M. oleifera</i> leaves extract  | Decreased wound size, improved wound contraction, and tissue regeneration, as well as downregulation of inflammatory mediators, such as TNF- $\alpha$ , IL-1 $\beta$ , IL-6, inducible nitric oxide synthase, and cyclooxygenase-2, and upregulate an angiogenic marker vascular endothelial growth factor in wound tissue | Vicenin-2 active compound may accelerate wound healing in hyperglycemic condition           | 90   |
|        | Bone protection       | Early osteoblasts resulting from neonatal rats  |       | <i>In vitro</i> , in 25 $\mu\text{g mL}^{-1}$ , 50 $\mu\text{g mL}^{-1}$ , 100 $\mu\text{g mL}^{-1}$ , and 150 $\mu\text{g mL}^{-1}$ , 1 g $\text{kg}^{-1}$ | <i>M. oleifera</i> polysaccharides | Reduced apoptosis and intracellular ROS levels in glucocorticoid-induced femoral necrosis. Decreased the expression of TNF- $\alpha$ and IL-6 genes with polysaccharide, and increased the expression of OCN, RUNX2 and COL-1 genes in cartilage tissue, protecting femoral head necrosis                                  | Controlling and regenerating osteoblasts cells, and preventing necrosis of the femoral head | 91   |








Fig. 10 Summary of the potential health benefits of *M. oleifera*. (Images were obtained from <http://figdraw.com/>).

improve hyperuricemia and metabolic disorders.<sup>107</sup> To verify the therapeutic effect of 1-*O*-(4-hydroxy-methylphenyl)- $\alpha$ -L-rhamnopyranoside (GR) in *M. oleifera* seeds on non-alcoholic fatty

liver disease (NAFLD), *in vitro* and *in vivo* experiments were established. The results showed that GR could significantly reduce intracellular fat deposition and ROS content, up-




Fig. 11 The common target of *M. oleifera* and 4 diseases obtained by the above screening was imported into the Metascape Data platform (<https://metascape.org/gp/index.html#/main/step1>).<sup>117</sup> The species was set to be "*Homo sapiens*", and GO function enrichment analysis and KEGG pathway enrichment was performed. GO functional analysis includes biological process (BP, biological process), cellular component (CC, cellular component), molecular function (MF, molecular function). It is visualized as histogram and bubble chart by the ImageGP (<https://www.bic.ac.cn/ImageGP/>).<sup>115</sup> KEGG enrichment analysis of potential targets of MOL in treating 4 diseases: arthritis (A), hypertension (B), diabetes (C), tumor (D).



regulate AMPK and peroxisome proliferator-activated receptor (PPAR $\alpha$ ), down-regulate Mechanistic Target of Rapamycin (mTOR) and sterol regulatory element binding transcription factor 1 (SREBP-1) to achieve liver lipid homeostasis. GR could also reduce serum fat content in high-fat diet mice, inhibit liver injury, and increase antioxidant mechanism, indicating that GR has hypolipidemia and liver protection activities. MOE water extract can drive vasodilation to reduce arterial blood pressure by stimulating endothelium-derived NO, providing a new method for the treatment of hypertension.<sup>108</sup>

### Other effects

Herbs therapy is widely used in the treatment of many diseases due to its low toxicity and good curative effect. Because the therapy affects reproductive physiology and improves certain infertility problems by acting on the hypothalamic–pituitary–gonadal axis.<sup>109</sup> *M. oleifera* is commonly prescribed by herbalists in Nigeria and other tropical countries to treat male infertility and female reproductive diseases.

Traditional plant medicines have often been used for wound treatment since ancient times. Besides the use of chemical drugs, high prices, side effects and other problems, herbal remedies have attracted attention.<sup>110</sup> *M. oleifera* is widely used in wound treatment due to its low side effects and excellent antioxidant and antibacterial activity. In addition to the above functions, *M. oleifera* can also be used for bone protection,<sup>91</sup> promote coagulation<sup>111</sup> and so on.

## Mechanism and components of *M. oleifera* in preventing and treating diseases

*M. oleifera* has been extensively studied for its pharmacological activity and function, and the mechanism of action of *M. oleifera* should be further elucidated at the molecular level. In this paper, from a network pharmacology perspective, we have explored the potential targets and molecular mechanisms of action of the major components of the *Moringa oleifera* leaves (MOL) against major diseases.

Combined with literature review and pharmacological action review results, cancer,<sup>7</sup> hypertension,<sup>112,113</sup> diabetes<sup>93</sup> and arthritis<sup>114</sup> were selected as potential treatment diseases of MOL. Refer to Table 2 for the results of UPLC-Q-TOF-MS analysis of the chemical composition of the MOL.

Metascape data platform was used to analyse the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment of MOL for diabetes, hypertension, arthritis and tumor intersections. The results showed that the main biological processes were icosanoid metabolic process, unsaturated fatty acid metabolic process, fatty acid metabolic process. Molecular functional targets are mainly related to heme binding, tetrapyrrole binding and oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen. The main enrichment items of the targets in cellular component are membrane raft, membrane microdomain and plasma membrane raft.

The enrichment results of KEGG pathway were sorted according to Partition coefficient value ( $-\log P$ ), and the top results were selected to draw a chart ( $P < 0.05$ )<sup>115</sup> (Fig. 11 and S1 to S4†). The results showed that the arthritis pathway was mainly enriched in: chemical carcinogenesis–DNA adducts, drug metabolism–cytochrome P450, linoleic acid metabolism, *et al.* In collagen-induced arthritis of rats, the linoleic acid metabolic pathway was significantly altered before and after treatment with 2-deoxy-D-glucose, suggesting that the linoleic acid metabolic pathway is closely related to the treatment of arthritis and may serve as a potential target.<sup>116</sup> And studies showed that the bezoar bile acid in the rheumatoid arthritis (RA) rats' body of the small molecule can affect the metabolic pathways of steroid hormone biosynthesis, which led to a decline in immune function in rats, by taking the *Atractylodes DC.*, and the metabolic pathway to normal levels, which can be speculated that by steroid hormones in the treatment of RA.<sup>45</sup>

Study on the major pathways of hypertension has shown that the haploidy insufficiency of glucocorticoid receptor in rats can cause the disorder of linoleic acid metabolism pathway.<sup>37</sup> Another study on the mechanism of melatonin-mediated hypotension, at 18 h, melatonin acted on the (cGMP-PKG) signaling pathway involved in NO synthesis, suggesting that the regulation of blood pressure could be achieved through the cGMP-PKG signaling pathway.<sup>118</sup>

According to KEGG pathway analysis of diabetes, there are drug metabolism–cytochrome P450, linoleic acid metabolism and Neuroactive ligand–receptor interaction, *et al.* Hogan *et al.* used quantitative reverse transcription Quantitative Real-time polymerase chain reaction (QRT-PCR) to identify differentially regulated gene expression of islet amyloid, which is associated with islet physiology and pathology of type II diabetes mellitus, and found that it contains steroidogenic acute regulatory protein (STAR protein), which is part of the synthetic response group of steroid hormone metabolism. It can be inferred that the pathway of steroid hormone metabolism is closely related to diabetes.<sup>119</sup> Resveratrol plays a protective role in the treatment of inflammation-induced vascular injury in type II diabetes by regulating NF- $\kappa$ B signaling pathway, suggesting that this signaling pathway has significant potential for type II diabetes and its complications.<sup>120</sup>

The results of KEGG pathway enrichment analysis suggested that amphiphysin (AMPH1), a protein at the nerve endings, plays an inhibitory role in ovarian cancer. Studies have demonstrated that AMPH1 inhibits the growth of tumor cells by inhibiting the growth of phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway in ovarian cancer.<sup>121</sup> Sadegh *et al.* studied the carcinogenic or anti-cancer effects of miRNA in cancer and apoptosis, and speculated that manipulating miRNA expression level might be a potential method to treat cancer.<sup>122</sup>

Based on the MOL composition–disease target–pathway network, combined with literature records and degree values, the main active components and targets of the MOL for different diseases were screened for molecular docking validation.<sup>123</sup> It is generally believed that the lower the conformational stability energy of the ligand and the receptor, the greater the



possibility of interaction, based on the choice of the degree value of the top core target in the corresponding active ingredient for docking as shown in Fig. S5.† The results show that there is a strong interaction between the target and the compound which score between  $-10.5 \sim -9.6 \text{ kcal mol}^{-1}$ . The core compound of arthritis, diabetes and tumour is rutin. The docking results with the lowest binding energies for the four diseases are shown in Fig. S6† respectively.

## Preparation formulations of *M. oleifera*

*M. oleifera* has numerous functions that are expected to be used to treat human diseases. Therefore, the selection of preparation formulation of *M. oleifera* should not be ignored. *M. oleifera* has been developed into granules, tablets, capsules, external preparation and other different preparation formulations such as nanoparticles. Additionally, the ingredient of *M. oleifera* can also be used as preparation excipients in the development of current drugs.

### Tablet and capsules

A tablet is a solid preparation of flake or profile-flake formed after uniform mixing of drug and excipient. Commonly, tablets are known to enhance drug dissolution and bioavailability, and has the advantages of stable quality, accurate dose, easy to take and carry. As for the choice of adhesive during the preparation of *M. oleifera* tablet, researchers carried on a detailed study with different adhesives including corn starch, gelatin and microcrystalline cellulose (MCC) and the water extract of *M. oleifera* leaves preparation of tablets, the formula were characterized using various parameters, such as the chemical and physical properties (bulk density tap water content, density ratio, Karr index ash value strength (fragility and crushing strength) and release properties (disintegration and dissolution time tests)).<sup>124,125</sup> The results showed that compared with MCC and corn starch, the tablets with gelatin as binder had the lowest brittleness and disintegration time, and the crushing strength was within the acceptable range (36 kgF). The comprehensive results showed that gelatin was the best adhesive for *M. oleifera* tablets. On the other hand, capsules are composed of is an active content with the appropriate auxiliary materials, either in the hollow hard capsule filling or seal in soft capsule material. *M. oleifera* have bitter taste, is not convenient to make direct oral powder, sealed with hard capsule or hollow capsule material, preparation into capsule not only can hide *M. oleifera* bad smell at the same time also can according to different drug purposes to achieve the location of drug release. *M. oleifera* leaves alcohol extract was prepared and standardized hard gelatin capsules (400 mg per capsule), in order to study the anti-obesity effect of *M. oleifera* leaves.<sup>126</sup> Fifteen female participants aged 45–55 years with a body mass index (BMI) of 29–34 kg m<sup>-2</sup> were selected for the test. The mean BMI total cholesterol (TC) and lowdensity lipoprotein (LDL) were significantly reduced in obese patients after taking *M. oleifera* capsules for eight weeks ( $P < 0.05$ ). Moreover, *M. oleifera* capsules can also be used as a natural emulsion to increase the volume of breast milk.<sup>127</sup>

### New preparation technology

The components of *M. oleifera* have been found to have low solubility bioavailability in drug preparation and poor compliance in common preparations due to their specific smell and taste. To improve the application and promotion of *M. oleifera* preparations, new preparation formulations have been gradually applied in it. Isothiocyanate extracted from *M. oleifera* (MITC) has excellent anti-skin photoaging effect, but its application is limited due to its extremely low water solubility, low bioavailability and easy degradation.<sup>16</sup> Therefore, they prepared amphiphilic hyaluronic acid (HA) conjugated with ceramide (CE) to modify nanoliposomes for MITC (HACE/MITC NPs) delivery. The results showed that the entrapment of MITC in nanoliposomes improves its stability, efficacy, and skin permeation. In addition, *M. oleifera* extract has been found to have mosquito repellent effect and can be used as a safe and cost-effective substitute for *N,N*-diethyl-3-methylbenzamide (DEET). Gelatin nanoparticles coated with *M. oleifera* bioactive extract were used to improve its availability.<sup>128</sup> Moreover, silver nanoparticles synthesized from *M. oleifera* leaf extract have also been found to have good anti-leishmania activity.<sup>129</sup> The treated fabric repellency to *Culex pipiens* mosquitoes showed stable 100% repellency for 6 days for all treated fabrics and ranged from 50 to 90% repellency after 12 days. Green synthesis of silver nanoparticles has been shown to have anticancer activity, Althomali *et al.* took *M. oleifera* leaf extract as the reducing agent and stabilizer of synthesize AgNPs, and the synthesized compound showed superior anticancer activity against human cancer cell line HTC116 and SW480 than *M. oleifera* leaf extract.<sup>130</sup> This result implies that AgNPs synthesized by *M. oleifera* extract could be an ideal strategy to combat colon cancer.

### Preparations for external use and others

In order to find a way to prevent 2019-nCoV through personal hygiene, researcher found that various components in *M. oleifera* leaves had antibacterial effects, for example: polyphenols, terpenoids, saponins, and so on.<sup>131</sup> The hand sanitizer is extracted by osmosis, and after processing, it can meet hand sanitizer quality standards and bacteriostatic standards. The hydrogel prepared with hexane extract of *M. oleifera* seeds has significant wound healing activity.<sup>89</sup> *M. oleifera* seed *n*-hexane water gel preparation can be used as a skin repair replacement therapy during wound healing. A membrane consisting of normalized water extract of oil tea leaf was then prepared for wound healing, which enhanced the proliferation and migration properties of human dermal fibroblasts and keratinocytes.<sup>132</sup> Study investigated the potential of *M. oleifera* seed polysaccharide (MOS-PS) and its composite with MOS-PS-AgNPs as an alternative material for wound dressing.<sup>24</sup> In addition, oral treatment of a predominantly *Leishmania* infected mouse model using silver nanoparticles biosynthesized from *M. oleifera* leaf extract (AG-NPs) was found to significantly reduce the mean size of skin lesions of leishmaniasis.<sup>133</sup> It was proved that the nanoparticles synthesized from *M. oleifera* leaf extract had good anti-leishmania activity.



## Pharmaceutical adjunct

*Moringa oleifera* is available in various dosage forms and due to its diverse composition, it can serve multiple purposes such as an emetic, a dissolvent, an adhesive, and a drug carrier. *M. oleifera* powder, although only slightly soluble in water, has the capability to expand and form a highly viscous solution, which can be used as an adhesive in the preparation of tablets.<sup>134</sup> The coagulated protein was extracted from *M. oleifera*, and its interface properties and interaction with sodium dodecyl sulfate (SDS) were studied. The results showed that the protein extracted from *M. oleifera* seeds had significant surfactant behavior and could be used as a surfactant. Therefore, moringa gum powder extracted from *M. oleifera* can also be used as disintegrating agent. On the basis of the research, moringa gum has potential as a binder and sustained-release agent in tablets.<sup>135</sup> Moreover, *in vitro* drug release studies have evaluated the sensitivity of moringa gum to colonic bacteria and tablets containing it have shown a drug release rate of 90.46%. According to the results, moringa gum could be used as a potential carrier for colonic specific drug delivery.<sup>136</sup>

## Future trends

On the one hand, herbal medicine can fully mobilize the human immune system through multi-target and multi-way synergistic effect, and play a radical cure effect. On the other hand, extensive toxicity experiments have proved its safety. Based on this, in recent years, medicinal plants and herbs have gradually become a treatment strategy for a variety of diseases. According to traditional ancient books, *M. oleifera* has multiple functions and plays a key role in curing and preventing diseases. As a medicinal and edible plant, *M. oleifera* has attracted extensive attention from countries around the world. How to study *M. oleifera*, an exotic species, with the help of traditional Chinese medical theory, and explain the pharmacological action and mechanism of its medicinal substance has become an opportunity and challenge for us to face. At the same time, the development of dietary supplements and adjuncts is inextricably linked to the design of prepared formulations, the selection of appropriate preparations, which can improve the stability and safety, in addition, enhance their efficacy. At present, *M. oleifera* only has common dosage forms such as granules, tablets, and capsules. Among the new preparations, only nano preparations have been studied, and the other preparation types are still to be developed. In addition, the development of current preparation types should start from the biopharmaceutical properties of *M. oleifera* itself, such as clarifying the solubility and permeability of relevant medicinal substances. In combination with different dosage forms, such as nano-pharmaceuticals, to improve the safety and stability of the *in vivo* bioavailability of the preparations.

## *M. oleifera* used in health products

Beyond its considerable medicinal properties, *M. oleifera* is also widely utilized in food industry, natural resource preservation

efforts, cosmeceuticals and other health product applications. Studies have demonstrated the nutritional benefits of incorporating *M. oleifera* leaves and buds into food products as a rich source of vitamins, minerals, and protein.<sup>137</sup> For instance, adding moringa bud powder (MSP) to conventional pasta has been shown to bolster the content of protein, lipid, fiber and minerals, while the content of carbohydrate showed a trend of decline. The addition of MSP also increases the levels of thiamine, riboflavin, gamma-aminobutyric acid, glucosinolate and antioxidant activity in pasta. Based on the sensory scores, the inclusion of MSP is a technical approach that can improve the nutritional value and biological activity of traditional pasta without compromising consumer acceptance.<sup>138</sup> From the perspective of nutrition, researchers have also developed a cheese product containing *M. oleifera* leaf powder. The aim is to increase the ash, protein, fiber and fat content of the product with the powder, so that cheese can be used as an alternative food in the fight against malnutrition.<sup>139</sup> *M. oleifera* is also widely used in baked goods. In response to consumer demand for organic food, moringa bread was developed by incorporating natural plant moringa leaves into baking product recipes. Studies have found that moringa bread products are more beneficial to human health because they are higher in nutrients and antioxidant activity than regular bread products, which contain less fiber and bioactive substances.<sup>140</sup> Besides, the addition of *M. oleifera* leaf to biscuits can also increase the iron and protein content of the product, while providing essential amino acids to the human body.<sup>141</sup> It is worth noting also *M. oleifera* contains large amounts of flavonoids and phenols, which have good antioxidant activity, so it can be used in the development of cosmeceuticals like body washes and lotions, as it is gentle on skin and helps to reduce irritation. For example, several studies have developed moringa-containing lotions by exploiting the properties of moringa, which can be used externally on the skin and have the properties of natural plant ingredients.<sup>64</sup> In addition to its ingredient properties, the addition of *M. oleifera* has the advantage of reducing skin irritation and improving the safety of the body wash.<sup>142</sup> As well as developing excellent emollient products using *M. oleifera* seed oil. Finally, *M. oleifera*'s biocoagulant capabilities make it a promising tool in natural resource management for water purification purposes. *M. oleifera* seed can remove turbidity and natural organic material to bring surface water up to standard requirements and it has the advantages of low-cost, simple operation, high efficiency and health safety.<sup>143</sup>

## Summary

*M. oleifera* is a kind of plant which can be used both as medicine and food. In this review the medicinal component of *M. oleifera* and the chemical components of each component of *M. oleifera* in combination with their functions was summarized, finding that MOL and MOS are currently the most widely used. It was found that the main components of *M. oleifera* are flavonoids and polyphenols. These bioactive compounds exhibit promising antioxidant, anti-inflammatory, anti-tumor, improve gut microbiota antibacterial, neuroprotective antioxidant,





ameliorate metabolic syndrome and other activities. Based on the pharmacological action and molecular mechanism was used to analyse the mechanism of *M. oleifera*, which may play a key role through PI3K-Akt signaling pathway in treating cancer and other diseases. Finally, the application of *M. oleifera* preparation, products and other format is reviewed. However, there are still some key questions that need to be answered through further studies: firstly, as an edible product, it is important to address the bitterness of *M. oleifera* for better future development. Next, although there have been several studies on the composition and function of *M. oleifera*, a more in-depth study of the unique composition, including structural and pharmacological aspects, is needed. Thirdly, the underlying mechanism of the MOL function is obtained from data calculations and simulation methods. To further confirm their correctness, *in vitro* and *in vivo* experiments should be designed for validation. Fourthly, it is found that research on *M. oleifera* preparation formulations mainly focused on traditional tablets, granules and capsules, etc. The preparation is relatively monotonous, and how to improve *M. oleifera's* bitter taste needs further research. In addition, the database used in this study is still constantly updated, so further research is needed to clarify the specific mechanism of *M. oleifera* on diseases, so as to better guide the development of functional foods and complementary drugs.

## Abbreviations

|                    |  |
|--------------------|--|
| <i>M. oleifera</i> | <i>Moringa oleifera</i> Lam.   |
| MOL                | <i>Moringa oleifera</i> Lam. leaves  |
| MOS                | <i>Moringa oleifera</i> Lam. seed  |
| UPLC-Q-TOF-MS      | Ultra High Performance Liquid Chromatography-Quadrupole-Time of Flight-Mass Spectrometry |
| ROS                | Reactive oxygen species  |
| NHDF               | Normal human dermal fibroblasts  |
| MOS-PS-AGNPs       | Silver nanocomposites with <i>M. oleifera</i> seed polysaccharides                       |
| IL-6               | Interleukin 6  |
| IL-17A             | Interleukin 17A  |
| IL-4               | Interleukin4   |
| IL-10              | Interleukin10  |
| INOS               | Inducible Nitric Oxide Synthase  |
| IL-1 $\beta$       | Interleukin1 $\beta$   |
| NQO1               | Quinone oxidoreductase 1   |
| HO-1               | Heme oxygenase 1   |
| CAT                | Catalase   |
| SOD                | Superoxide dismutase   |
| GPX                | Glutathione peroxidase   |
| COX-2              | Cyclooxygenase-2   |
| A549               | Human non small cell lung cancer cell  |
| JAK2               | Janus kinase2  |
| STAT3              | Signal Transducer and Activator of Transcription 3                                       |
| PCR                | Polymerase Chain Reaction  |
| MSE                | <i>M. oleifera</i> seed extract  |
| cGMP-PKG           | cGMP-dependent protein kinase  |

|                     |   |
|---------------------|---|
| MOs-2-a             | A polysaccharide separated from <i>M. oleifera</i> leaf             |
| DEHP                | Di-(2-ethylhexyl) phthalate   |
| Nrf2                | Factor erythro2-related factor 2                                    |
| ER stress           | Endoplasmic reticulum stress  |
| NZ                  | Niazimicin  |
| GSH                 | Glutathione   |
| MDA                 | Malondialdehyde   |
| NF- $\kappa$ B      | Nuclear factor kappa-B  |
| FA                  | Fatty acids   |
| AMPK                | AMP-activated Protein Kinase  |
| MOLH                | <i>M. oleifera</i> leaf hydrolysate                                 |
| GR                  | 1- <i>O</i> -(4-Hydroxy-methylphenyl)- $\alpha$ -L-rhamnopyranoside |
| PPAR $\alpha$       | Peroxisome proliferator-activated receptor                          |
| mTOR                | Mechanistic Target Of Rapamycin                                     |
| SREBP-1             | Sterol regulatory element binding transcription factor 1            |
| GO                  | Gene ontology   |
| KEGG                | Kyoto Encyclopedia of Genes and Genomes                             |
| –log <i>P</i> value | Partition coefficient value   |
| RA                  | Rheumatoid arthritis  |
| QRT-PCR             | Quantitative Real-time polymerase chain reaction                    |
| STAR protein        | Steroidogenic acute regulatory protein                              |
| AMPH1               | Amphiphysin   |
| PI3K/AKT            | Phosphatidylinositol 3 kinase/protein kinase B                      |
| MCC                 | Microcrystalline cellulose  |
| TC                  | Total cholesterol   |
| LDL                 | Lowdensity lipoprotein  |
| MITC                | Isothiocyanate extracted from <i>M. oleifera</i>                    |
| HA                  | Hyaluronic acid   |
| CE                  | Conjugated with ceramide  |
| DEET                | <i>N,N</i> -Diethyl-3-methylbenzamide                               |
| MOS-PS              | <i>M. oleifera</i> seed polysaccharide                              |
| AG-NPs              | <i>M. oleifera</i> leaf extract                                     |
| SDS                 | Sodium dodecyl sulfate  |
| MSP                 | Moringa bud powder  |
| DPPH                | 2,2-Diphenyl-1-picrylhydrazyl                                       |
| ABTS                | 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)              |
| LPO                 | Lactoperoxidase   |
| AGES                | Advanced glycation end-products                                     |
| Bax                 | BCL <sub>2</sub> -associated X protein                              |
| BCL <sub>2</sub>    | B-Cell lymphoma-2   |
| ACE                 | Angiotensin I-converting enzyme                                     |
| IL-3                | Interleukin-3   |
| STAT5               | Signal Transducer and Activator of Transcription 5                  |
| UVB                 | Ultraviolet radiation b   |
| MMP-1               | Matrix metalloproteinase 1  |
| MMP-3               | Matrix metalloproteinase 3  |
| MMP-9               | Matrix metalloproteinase 9  |
| TNF- $\alpha$       | Tumor necrosis factors- $\alpha$                                    |
| IAVS                | Influenza A viruses   |
| GSK-3 $\beta$       | Glycogen synthase kinase-3 $\beta$                                  |
| antibody            |   |
| DDPH                | 2,2-Diphenyl-1-picrylhydrazyl                                       |
| ORAC                | Oxygen Radical Absorption Capacity                                  |





## Review

|                     |   |
|---------------------|---|
| TLR4                | Toll-like receptor 4                              |
| T-47D               | Human breast ductal carcinoma cells               |
| CD31                | Platelet endothelial cell adhesion molecule-1     |
| Smac                | Second mitochondria-derived activator of caspases |
| HSP 70              | Heat shock protein 70                             |
| Skp2                | S-Phase kinase-associated protein 2               |
| Fbw7 $\alpha$       | F-Box and WD repeat domain-containing7 $\alpha$   |
| INF- $\kappa$ B     | Nuclear factor kappa-B inhibitor                  |
| ERK                 | Extracellular-signal-regulated kinase             |
| TGF- $\beta$        | Transforming growth factor beta                   |
| IFN- $\gamma$       | Interferon-gamma                                  |
| Th2                 | T-Helper cell type 2                              |
| NAFLD               | Non-alcoholic fatty liver disease                 |
| HFD                 | Histone fold domain                               |
| p <sup>22phox</sup> | Cytochrome b-245, alpha polypeptide               |
| p <sup>47phox</sup> | Phospho-Ser359                                    |
| RUNX2               | Runt-related transcription factor 2               |
| COL-1               | Collagentypel 1                                   |

## Author contributions

Xinyue Su, Guanzheng Lu, Liang Ye Maomao Zhu and Xinming Yu collected and analysed the literature data. Xinyue Su and Guanzheng Lu completed the network pharmacology and UPLC-Q-TOF-MS. Xinyue Su and Ruyu Shi was also responsible for writing and submission of this manuscript. Liang Ye and Xinming Yu revised the format of the article. Xinbin Jia, Zhiyong Li and Liang Feng participated in reviewing and proofreading this manuscript. All authors read and approved the final manuscript. All data were generated inhouse, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.

## Conflicts of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, there is no professional or other personal interest of any nature or kind in any product, service or company that could be construed as influencing the position.

## Acknowledgements

This work was supported by Key research projects on modernization of traditional Chinese medicine, National Key R&D Program (2018YFC1706900). "Double First-Class" University project of China Pharmaceutical University (CPU2018GF07, CPU2018PZQ19). The protein targets of the active substances in *M. oleifera* were retrieved from the Swiss Target Prediction database (<http://www.swisstargetprediction.ch/>).<sup>144</sup> Diseases-related human genes were collected from three databases, namely, Online Mendelian Inheritance in Man (OMIM, <http://www.omim.org>), Therapeutic Target Database (TTD, <https://db.idrblab.org/ttd/>),<sup>145</sup> and DrugBank (<https://www.drugbank.ca>). The PPI network of *M. oleifera* and

diseases intersection targets were obtained on the String11.5 platform (<http://string-db.org/>).<sup>146</sup> The gene ontology (GO) and pathway enrichment analyses were conducted using the functional annotation tool of Metascape Data platform (<https://metascape.org/gp/index.html#/main/step1>).<sup>117</sup> The compound-target and target-pathway networks were generated using Cytoscape 3.7.1.<sup>147</sup> The 3D structure of the key target proteins was downloaded from PDB database (<http://www.wwpdb.org/>).<sup>148</sup>

## References

- 1 Y. Bao, J. Xiao, Z. Weng, X. Lu, X. Shen and F. Wang, *Food Chem.*, 2020, **311**, 125948.
- 2 N. Bennour, H. Mighri, T. Bouhamda, M. Mabrouk, E. Apohan, O. Yesilada, H. Küçükbay and A. Akrouit, *Prep. Biochem. Biotechnol.*, 2021, **51**, 1018–1025.
- 3 F. Wang, Y. Bao, C. Zhang, L. Zhan, W. Khan, S. Siddiqua, S. Ahmad, E. Capanoglu, K. Skalicka-Woźniak, L. Zou, J. Simal-Gandara, H. Cao, Z. Weng, X. Shen and J. Xiao, *Crit. Rev. Food Sci. Nutr.*, 2021, 1–25.
- 4 J. Xie, L. J. Peng, M. R. Yang, W. W. Jiang, J. Y. Mao, C. Y. Shi, Y. Tian and J. Sheng, *J. Evidence-Based Complementary Altern. Med.*, 2021, **2021**, 5591687.
- 5 H. Yang, X. Shao and M. Wu, *Sustainability.*, 2019, **11**, 4908.
- 6 F. Al Juhaimi, K. Ghafoor, I. A. M. Ahmed, E. E. Babiker and M. M. Özcan, *J. Food Meas. Char.*, 2017, **11**, 1745–1751.
- 7 B. H. Do, N. S. Hoang, T. P. T. Nguyen, N. Q. C. Ho, T. L. Le and C. C. Doan, *Nutr. Cancer*, 2021, **73**, 869–888.
- 8 S. Chandrashekar, R. Vijayakumar, R. Chelliah, E. B.-M. Daliri, I. H. Madar, G. Sultan, M. Rubab, F. Elahi, S.-J. Yeon and D.-H. Oh, *Molecules*, 2021, **26**, 2080.
- 9 L. R. Managa, E. S. du Toit and G. Prinsloo, *Molecules*, 2021, **26**, 2298.
- 10 K. Kerdsomboon, W. Chumsawat and C. Auesukaree, *Chemosphere*, 2021, **270**, 128659.
- 11 F. Wang, Y. Bao, C. Zhang, L. Zhan, W. Khan, S. Siddiqua, S. Ahmad, E. Capanoglu, K. Skalicka-Woźniak, L. Zou, J. Simal-Gandara, H. Cao, Z. Weng, X. Shen and J. Xiao, *Crit. Rev. Food Sci. Nutr.*, 2021, **62**, 3873–3897.
- 12 J. Laoung-on, K. Saenphet, C. Jaikang and P. Sudwan, *Plants*, 2021, **10**, 2019.
- 13 B. S. Ogunsina, C. Radha and R. S. Govardhan Singh, *Int. J. Food Sci. Technol.*, 2010, **45**, 2433–2439.
- 14 M. M. Özcan, *S. Afr. J. Bot.*, 2020, **129**, 25–31.
- 15 F. Al Juhaimi, K. Ghafoor, E. E. Babiker, B. Matthäus and M. M. Özcan, *J. Food Biochem.*, 2017, **41**, e12322.
- 16 Y. Wang, Q. Ouyang, X. Chang, M. Yang, J. He, Y. Tian and J. Sheng, *Drug Delivery*, 2022, **29**, 871–881.
- 17 Â. Fernandes, A. Bancessi, J. Pinela, M. I. Dias, Â. Liberal, R. C. Calhelha, A. Ćirić, M. Soković, L. Catarino, I. C. F. R. Ferreira and L. Barros, *Food Chem.*, 2021, **341**, 128229.
- 18 J. Punia and R. Singh, *Orient. J. Chem.*, 2018, **34**, 1589–1596.
- 19 A. K. Singhal, E. E. Jarald, A. Showkat and A. Daud, *Int. J. Pharm. Invest.*, 2012, **2**, 48–51.



- 20 M. Tekayev, N. Bostancieri, K. A. S. M. Saadat, M. Turker, M. Yuncu, H. Ulusal, H. Cicek and K. Arman, *Gene*, 2019, **688**, 140–150.
- 21 A. Tesfaye, A. Anjulo, A. Fekadu, K. Beyene, A. Girma, B. Gameda, G. Temesgen, F. Wolde, E. Mulugeta and A. Manilal, *PLoS One*, 2022, **17**, e0274678.
- 22 I. J. Asiedu-Gyekye, S. Frimpong-Manso, C. Awortwe, D. A. Antwi and A. K. Nyarko, *J. Toxicol.*, 2014, **2014**, 786979.
- 23 S. Siddiqui, S. Upadhyay, I. Ahmad, A. Hussain and M. Ahamed, *J. Food Biochem.*, 2021, **45**, e13720.
- 24 H. M. Mehwish, G. Liu, M. S. R. Rajoka, H. Cai, J. Zhong, X. Song, L. Xia, M. Wang, R. M. Aadil, M. Inam-Ur-Raheem, Y. Xiong, H. Wu, M. I. Amirzada, Q. Zhu and Z. He, *Int. J. Biol. Macromol.*, 2021, **184**, 144–158.
- 25 D. Teshome, C. Tiruneh and G. Berihun, *BioMed Res. Int.*, 2021, **2021**, 5291083.
- 26 A. F. Attah, J. O. Moody, M. A. Sonibare, H. H. Salahdeen, O. O. Akindele, P. O. Nnamani, O. A. Diyaolu and Y. Raji, *S. Afr. J. Bot.*, 2020, **129**, 255–262.
- 27 N. Bennour, H. Mighri, T. Bouhamda, M. Mabrouk, E. Apohan, O. Yesilada, H. Küçükbay and A. Akrouit, *Prep. Biochem. Biotechnol.*, 2021, **51**, 1018–1025.
- 28 S. Tariq, H. Umbreen, R. Noreen, C. Petitbois, K. Aftab, F. A. Alasmay, A. S. Almalki and M. A. Mazid, *BioMed Res. Int.*, 2022, **2022**, 4987929.
- 29 O. H. Oyeniran, A. O. Ademiluyi and G. Oboh, *J. Food Biochem.*, 2021, **45**, e13401.
- 30 F. Alia, M. Putri, N. Anggraeni and M. R. A. A. Syamsunarno, *Front. Pharmacol.*, 2022, **12**, 724439.
- 31 W. Khan, R. Parveen, K. Chester, S. Parveen and S. Ahmad, *Front. Pharmacol.*, 2017, **8**, 577.
- 32 J. Laoung-on, K. Saenphet, C. Jaikang and P. Sudwan, *Plants*, 2021, **10**, 2019.
- 33 A. Nair D, T. J. James, S. L. Sreelatha, B. J. Kariyil and S. N. Nair, *Nat. Prod. Res.*, 2021, **35**, 6216–6222.
- 34 O. I. Fantoukh, Y. H. Wang, A. Parveen, M. F. Hawwal, G. A. Al-Hamoud, Z. Ali, A. G. Chittiboyina and I. A. Khan, *Planta Med.*, 2021, **87**, 417–427.
- 35 B. H. Do, N. S. Hoang, T. P. T. Nguyen, N. Q. C. Ho, T. L. Le and C. C. Doan, *Nutr. Cancer*, 2021, **73**, 869–888.
- 36 F. Dhawi, S. E.-B. H. E. Aly and A. M. Hamed, *Foods*, 2020, **9**, 1157.
- 37 P. Sharma, J. Wichaphon and W. Klangpetch, *Int. J. Food Microbiol.*, 2020, **332**, 108770.
- 38 A. Saleem, M. Saleem and M. F. Akhtar, *S. Afr. J. Bot.*, 2020, **128**, 246–256.
- 39 S. Muhammad, S. H. Hassan, A. G. Al-Sehemi, H. A. Shakir, M. Khan, M. Irfan and J. Iqbal, *Chem. Phys. Lett.*, 2021, **767**, 138379.
- 40 Z. Dou, C. Chen and X. Fu, *Food Funct.*, 2019, **10**, 5070–5079.
- 41 T. Rodríguez-García, B. H. Camacho-Díaz, A. R. Jiménez-Aparicio, J. Santaolalla-Tapia, S. Evangelista-Lozano and M. L. Arenas-Ocampo, *Rev. Bras. Farmacogn.*, 2021, **31**, 302–309.
- 42 Y.-Y. Wu, Y.-M. Xu and A. T. Y. Lau, *Molecules*, 2021, **26**, 7512.
- 43 D. Barhoi, P. Upadhaya, S. N. Barbhuiya, A. Giri and S. Giri, *J. Am. Coll. Nutr.*, 2021, **40**, 70–85.
- 44 C. Michl, F. Vivarelli, J. Weigl, G. R. De Nicola, D. Canistro, M. Paolini, R. Iori and A. Rasclé, *PLoS One*, 2016, **11**, e0157430.
- 45 Y. Liu, B. Zhang and Q. Cai, *Biomed. Pharmacother.*, 2020, **131**, 110554.
- 46 A. Jaja-Chimedza, L. Zhang, K. Wolff, B. L. Graf, P. Kuhn, K. Moskal, R. Carmouche, S. Newman, J. M. Salbaum and I. Raskin, *J. Funct. Foods*, 2018, **47**, 376–385.
- 47 Y. Wen, W. Li, R. Su, M. Yang, N. Zhang, X. Li, L. Li, J. Sheng and Y. Tian, *Front. Microbiol.*, 2022, **13**, 925291.
- 48 W. Wang, J. Jin, H. Xu, Y. Shi, M. Boersch and Y. Yin, *J. Ethnopharmacol.*, 2022, **285**, 114894.
- 49 Y. N. Feng and X. F. Zhang, *Int. J. Biol. Macromol.*, 2020, **157**, 267–275.
- 50 T. B. He, Y. P. Huang, Y. Huang, X. J. Wang, J. M. Hu and J. Sheng, *Int. J. Biol. Macromol.*, 2018, **112**, 126–133.
- 51 K. Sharma, M. Kumar, R. Waghmare, R. Suhag, O. P. Gupta, J. M. Lorenzo, P. S. Radha, N. Rais, V. Sampathrajan, C. Thappa, T. Anitha, A. A. S. Sayed, B. A. Abdel-Wahab, M. Senapathy, R. Pandiselvam, A. Dey, S. Dhumal, R. Amarowicz and J. F. Kennedy, *Int. J. Biol. Macromol.*, 2022, **209**, 763–778.
- 52 H. Tian, Y. Liang, G. Liu, Y. Li, M. Deng, D. Liu, Y. Guo and B. Sun, *Int. J. Biol. Macromol.*, 2021, **182**, 595–611.
- 53 Y. Yang, M. Zhao and L. Lin, *Int. J. Food Sci. Technol.*, 2020, **55**, 1539–1546.
- 54 Z. Wen, H. Tian, Y. Liang, Y. Guo, M. Deng, G. Liu, Y. Li, D. Liu and B. Sun, *Int. J. Biol. Macromol.*, 2022, **198**, 135–146.
- 55 Q. Zhao, L. He, X. Wang, X. Ding, L. Li, Y. Tian and A. Huang, *J. Agric. Food Chem.*, 2022, **70**, 6123–6133.
- 56 S. Avilés-Gaxiola, J. León-Félix, Y. B. Jiménez-Nevárez, M. A. Angulo-Escalante, R. Ramos-Payán, J. Colado-Velázquez and J. B. Heredia, *S. Afr. J. Bot.*, 2021, **141**, 466–473.
- 57 P. E. Vanderriele, Q. Wang, A. M. Mérillat, F. Ino, G. Aeschlimann, X. Ehret, D. Ancin Del Olmo, V. Ponce de León, U. I. Scholl, D. V. Winter, A. Odermatt, E. Hummler and S. N. Verouti, *Int. J. Mol. Sci.*, 2021, **22**, 13218.
- 58 Y. Xiong, M. S. Riaz Rajoka, M. Zhang and Z. He, *Nat. Prod. Res.*, 2022, **36**, 974–983.
- 59 Y. Xiong, M. S. R. Rajoka, H. M. Mehwish, M. Zhang, N. Liang, C. Li and Z. He, *Int. Immunopharmacol.*, 2021, **95**, 107561.
- 60 L. L. d. S. Patriota, D. d. B. M. Ramos, M. Gama e Silva, A. C. L. A. dos Santos, Y. A. Silva, A. d. O. Marinho, L. C. B. B. Coelho, P. M. G. Paiva, E. V. Pontual, R. L. Mendes and T. H. Napoleão, *S. Afr. J. Bot.*, 2021, **143**, 474–481.
- 61 L.-l. Liang, S.-y. Cai, M. Gao, X.-m. Chu, X.-y. Pan, K.-K. Gong, C.-w. Xiao, Y. Chen, Y.-q. Zhao, B. Wang and K.-l. Sun, *J. Funct. Foods*, 2020, **64**, 103698.
- 62 Y. Wen, Y. Liu, Q. Huang, R. Liu, J. Liu, F. Zhang, S. Liu and Y. Jiang, *Phytomedicine*, 2022, **95**, 153856.



- 63 A. Jaja-Chimedza, B. L. Graf, C. Simmler, Y. Kim, P. Kuhn, G. F. Pauli and I. Raskin, *PLoS One*, 2017, **12**, e0182658.
- 64 S. M. Fathy and M. S. Mahmoud, *Food Sci. Hum. Wellness*, 2021, **10**, 383–391.
- 65 D. A. Nair, T. J. James, S. L. Sreelatha, B. J. Kariyil and S. N. Nair, *Nat. Prod. Res.*, 2021, **35**, 6216–6222.
- 66 W. Dalhousi, F. Guesmi, A. Bouzidi, S. Akermi, N. Hfaiedh and I. Saidi, *Saudi J. Biol. Sci.*, 2022, **29**, 103284.
- 67 M. E. Abdel Fattah, H. M. Sobhy, A. Reda and H. M. A. Abdelrazek, *Environ. Sci. Pollut. Res.*, 2020, **27**, 43028–43043.
- 68 U. F. Mohd Fisall, N. Z. Ismail, I. A. Adebayo and H. Arsad, *Mol. Biol. Rep.*, 2021, **48**, 4465–4475.
- 69 E. R. M. Zunica, S. Yang, A. Coulter, C. White, J. P. Kirwan and L. A. Gilmore, *Nutrients*, 2021, **13**, 2923.
- 70 C. Tiloke, A. Phulukdaree, K. Anand, R. M. Gengan and A. A. Chuturgoon, *J. Cell. Biochem.*, 2016, **117**, 2302–2314.
- 71 L. Hagoel, A. Vexler, L. Kalich-Philosoph, G. Earon, I. Ron, A. Shtabsky, S. Marmor and S. Lev-Ari, *Integr. Cancer Ther.*, 2019, **18**, 1534735419828829.
- 72 M. L. Cuellar-Nuñez, I. Luzardo-Ocampo, R. Campos-Vega, M. A. Gallegos-Corona, E. González de Mejía and G. Loarca-Piña, *Food Res. Int.*, 2018, **105**, 159–168.
- 73 K. M. Sadek, T. K. Abouzed, R. Abouelkhair and S. Nasr, *Pharm. Biol.*, 2017, **55**, 1458–1466.
- 74 L. L. d. S. Patriota, D. d. B. M. Ramos, A. C. L. A. dos Santos, Y. A. Silva, M. Gama e Silva, D. J. L. Torres, T. F. Procópio, A. M. de Oliveira, L. C. B. B. Coelho, E. V. Pontual, D. C. N. da Silva, P. M. G. Paiva, V. M. B. de Lorena, R. L. Mendes and T. H. Napoleão, *Food Chem. Toxicol.*, 2020, **145**, 111691.
- 75 M. Abdel-Latif, G. El-Shahawi, S. M. Aboelhadid and H. Abdel-Tawab, *J. Helminthol.*, 2018, **92**, 142–153.
- 76 L. Jia, X. Peng, Z. Deng, B. Zhang and H. Li, *Food Biosci.*, 2023, **52**, 102482.
- 77 M. Amina, R. S. Bhat, A. M. Al-Dbass, N. M. Musayeib, R. Fahmy, L. Alhadlaq and A. El-Ansary, *PeerJ*, 2021, **9**, e11569.
- 78 L. Romeo, F. Diomede, A. Gugliandolo, D. Scionti, F. Lo Giudice, V. Lanza Cariccio, R. Iori, P. Bramanti, O. Trubiani and E. Mazzon, *Sci. Rep.*, 2018, **8**, 9153.
- 79 Y. Jiang, R. Liu, J. Li, Q. Huang, S. Liu and J. He, *Phytochemistry*, 2022, **204**, 113451.
- 80 A. Razaq, S. Ahmad Malik, F. Saeed, A. Imran, A. Rasul, M. Qasim, S. Zafar, S. K. S. Kamran, J. Maqbool, M. Imran, G. Hussain and M. Hussain, *Food Sci. Nutr.*, 2020, **8**, 4009–4016.
- 81 M. Liao, C. Sun, R. Li, W. Li, Z. Ge, M. Adu-Frimpong, X. Xu and J. Yu, *Food Chem.*, 2022, **379**, 132087.
- 82 W. T. Muzumbukilwa, M. Nlooto and P. M. O. Owira, *J. Funct. Foods*, 2019, **57**, 75–82.
- 83 L. E. Díaz-Prieto, S. Gómez-Martínez, I. Vicente-Castro, C. Heredia, E. A. González-Romero, M. D. C. Martín-Ridaura, M. Ceinos, M. J. Picón, A. Marcos and E. Nova, *Nutrients*, 2022, **14**, 1937.
- 84 H. Joung, B. Kim, H. Park, K. Lee, H.-H. Kim, H.-C. Sim, H.-J. Do, C.-K. Hyun and M.-S. Do, *J. Med. Food*, 2017, **20**, 439–447.
- 85 C. Waterman, J. L. Graham, C. D. Arnold, K. L. Stanhope, J. H. Tong, A. Jaja-Chimedza and P. J. Havel, *Sci. Rep.*, 2020, **10**, 8861.
- 86 J. I. Randriamboavonjy, M. Rio, P. Pacaud, G. Loirand and A. Tesse, *Oxid. Med. Cell. Longevity*, 2017, **2017**, 4129459.
- 87 B. Zeng, J. Luo, P. Wang, L. Yang, T. Chen, J. Sun, M. Xie, M. Li, H. Zhang, J. He, Y. Zhang and Q. Xi, *Food Sci. Nutr.*, 2019, **7**, 738–746.
- 88 P. K. Ajuogu, O. O. Mgbere, D. S. Bila and J. R. McFarlane, *J. Ethnopharmacol.*, 2019, **233**, 80–86.
- 89 A. Ali, P. Garg, R. Goyal, G. Kaur, X. Li, P. Negi, M. Valis, K. Kuca and S. Kulshrestha, *Plants*, 2020, **10**, 25.
- 90 A. A. Muhammad, P. Arulselvan, P. S. Cheah, F. Abas and S. Fakurazi, *Drug Des., Dev. Ther.*, 2016, **10**, 1715–1730.
- 91 B. Zhang, C. Lu, Z. Xu, H. Guo, G. Zhang and Y. Hao, *Arabian J. Chem.*, 2022, **15**, 103410.
- 92 I. A. Adebayo, H. Arsad, N. N. S. b. N. M. Kamal and M. R. Samian, *S. Afr. J. Bot.*, 2020, **129**, 379–387.
- 93 M. J. Tuorkey, *Interv. Med. Appl. Sci.*, 2016, **8**, 109–117.
- 94 F. Wang, S. Long and J. Zhang, *Arch. Oral Biol.*, 2021, **132**, 105280.
- 95 T. P. Omayone, O. M. Ijomone, S. B. Oloyede, S. T. Okunola, Z. O. Aigoro, V. U. Esukpa and S. O. Dinakin, *J. Basic Clin. Physiol. Pharmacol.*, 2021, DOI: [10.1515/jbcpp-2021-0149](https://doi.org/10.1515/jbcpp-2021-0149), **000010151520210149**.
- 96 I. Buchwalow, J. Schnekenburger, D. Atiakshin, V. Samoilova, E. Wolf, W. Boecker and K. Tiemann, *Acta Histochem.*, 2017, **119**, 252–256.
- 97 Y. Wang, O. Andrukhov and X. Rausch-Fan, *Front. Physiol.*, 2017, **8**, 910.
- 98 P. Lepetsos and A. G. Papavassiliou, *Biochim. Biophys. Acta*, 2016, **1862**, 576–591.
- 99 A. M. Tomsa, A. L. Alexa, M. L. Junie, A. L. Rachisan and L. Ciumarnean, *PeerJ*, 2019, **7**, e8046.
- 100 T. Mitani, Y. Yoshioka, T. Furuyashiki, Y. Yamashita, Y. Shirai and H. Ashida, *Free Radical Biol. Med.*, 2017, **106**, 355–367.
- 101 K. H. Alzoubi, N. Q. Rawashdeh, O. F. Khabour, T. El-Elimat, H. Albataineh, H. M. Al-Zghool and F. Q. Alali, *J. Mol. Neurosci.*, 2017, **63**, 355–363.
- 102 B. H. Do, T. P. T. Nguyen, N. Q. C. Ho, T. L. Le, N. S. Hoang and C. C. Doan, *Mol. Biol. Rep.*, 2020, **47**, 3675–3689.
- 103 F. Wang, Y. F. Bao, J. J. Si, Y. Duan, Z. B. Weng and X. C. Shen, *J. Med. Food*, 2019, **22**, 907–918.
- 104 I. Amara, M. L. Ontario, M. Scuto, G. M. Lo Dico, S. Sciuto, V. Greco, S. Abid-Essefi, A. Signorile, A. T. Salinaro and V. Calabrese, *Antioxidants*, 2021, **10**, 532.
- 105 E. M. Abdelsayed, D. Medhat, Y. M. Mandour, R. S. Hanafi and A. A. Motaal, *J. Food Biochem.*, 2021, **45**, e13992.
- 106 J. Tabeshpour, B. M. Razavi and H. Hosseinzadeh, *Phytother. Res.*, 2017, **31**, 819–837.
- 107 Y. Tian, L. Lin, M. Zhao, A. Peng and K. Zhao, *J. Ethnopharmacol.*, 2021, **270**, 113808.



- 108 D. Aekthammarat, P. Tangsucharit, P. Pannangpetch, T. Sriwantana and N. Sibmooh, *Biomed. Pharmacother.*, 2020, **130**, 110605.
- 109 K. Ried, *Compl. Ther. Med.*, 2015, **23**, 116–128.
- 110 S. Ning, J. Zang, B. Zhang, X. Feng and F. Qiu, *Front. Pharmacol.*, 2022, **13**, 885484.
- 111 A. Satish, S. Sairam, F. Ahmed and A. Urooj, *Pharmacogn. Res.*, 2012, **4**, 44–49.
- 112 S. M. Ezzat, M. H. E. Bishbishy, N. M. Aborehab, M. M. Salama, A. Hasheesh, A. A. Motaal, H. Rashad and F. M. Metwally, *J. Ethnopharmacol.*, 2020, **251**, 112541.
- 113 K. Ma, Y. Wang, M. Wang, Z. Wang, X. Wang, X. Ju and R. He, *Food Funct.*, 2021, **12**, 8994–9006.
- 114 M. H. Jameel, K. N. A. Karim, A. M. Z. Bin, M. Roziathanim and A. L. M. Vikneswaran, *Integr. Med. Res.*, 2018, **7**, 85–94.
- 115 T. Chen, Y.-X. Liu and L. Huang, *iMeta*, 2022, **1**, e5.
- 116 H. Wang, N. Zhang, K. Fang and X. Chang, *Front. Immunol.*, 2021, **12**, 713799.
- 117 Y. Zhou, B. Zhou, L. Pache, M. Chang, A. H. Khodabakhshi, O. Tanaseichuk, C. Benner and S. K. Chanda, *Nat. Commun.*, 2019, **10**, 1523.
- 118 G. Shao, S. Zhang, J. Nie, J. Li and J. Tong, *J. Toxicol. Environ. Health, Part A*, 2017, **80**, 1342–1348.
- 119 M. F. Hogan, Z. Mark, K. N. Harikrishnan, R. Hanah, K. Antony, E. Nathalie, T. A. T. E. Assam and S. E. Kahn, *Protein Eng., Des. Sel.*, 2019, **32**, 67–76.
- 120 X. Zheng, S. Zhu, S. Chang, Y. Cao, J. Dong, J. Li, R. Long and Y. Zhou, *Eur. J. Pharmacol.*, 2013, **720**, 147–157.
- 121 C. Yajun, C. Wenjiao, W. Lihua and Z. Tianying, *J. Cell. Mol. Med.*, 2020, **24**, 7652–7659.
- 122 S. Babashah and M. Soleimani, *Eur. J. Cancer*, 2011, **47**, 1127–1137.
- 123 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455–461.
- 124 J. Muazu and Z. A. Suleiman, *J. Pharm. Res. Int.*, 2014, **4**, 2261–2272.
- 125 K. Al-Khafaji and T. Taskin Tok, *Comput. Methods Progr. Biomed.*, 2020, **195**, 105660.
- 126 S. M. Ezzat, M. H. El Bishbishy, N. M. Aborehab, M. M. Salama, A. Hasheesh, A. A. Motaal, H. Rashad and F. M. Metwally, *J. Ethnopharmacol.*, 2020, **251**, 112541.
- 127 S. Fungtammasan and V. Phupong, *PLoS One*, 2021, **16**, e0248950.
- 128 N. M. Hani, A. E. Torkamani, M. H. Azarian, K. W. Mahmood and S. H. Ngalim, *J. Sci. Food Agric.*, 2017, **97**, 3348–3358.
- 129 A. A. El-Sayed, A. Amr, O. M. H. M. Kamel, M. M. T. El-Saidi and A. E. Abdelhamid, *Cellulose*, 2020, **27**, 8429–8442.
- 130 A. Althomali, M. H. Daghestani, F. Basil Almukaynizi, S. A. Al-Zahrani, M. A. Awad, N. M. Merghani, W. I. Bukhari, E. M. Ibrahim, S. M. Alzahrani, N. Altowair, A. S. Al-Ghamdi, A. M. AlQahtani, R. Ramadan and R. S. Bhat, *Green Process. Synth.*, 2022, **11**, 545–554.
- 131 F. Arifan, R. W. Broto, E. F. Sapatra and A. Pujiastuti, *IOP Conf. Ser. Earth Environ. Sci.*, 2021, **623**, 012015.
- 132 C. Y. Chin, J. Jalil, P. Y. Ng and S. F. Ng, *J. Ethnopharmacol.*, 2017, **212**, 188–199.
- 133 M. El-Khadragy, E. M. Alolayan, D. M. Metwally, M. F. S. El-Din, S. S. Alobud, N. I. Alsultan, S. S. Alsaif, M. A. Awad and A. E. Abdel Moneim, *Int. J. Environ. Res. Public Health*, 2018, **15**, 1037.
- 134 B. Uphadek, M. Shinkar D., B. Patil P. and B. Saudagar R., *Int. J. Curr. Pharm. Res.*, 2018, **10**, 13–16.
- 135 D. S. Panda, N. S. K. Choudhury, M. Yedukondalu, S. Si and R. Gupta, *Indian J. Pharm. Sci.*, 2008, **70**, 614–618.
- 136 A. K. Singhal, E. E. Jarald, A. Showkat and A. Daud, *Int. J. Pharm. Invest.*, 2012, **2**, 48–51.
- 137 A. T. Oyeyinka and S. A. Oyeyinka, *J. Saudi Soc. Agric. Sci.*, 2018, **17**, 127–136.
- 138 K. E. Coello, E. Peñas, C. Martinez-Villaluenga, M. Elena Cartea, P. Velasco and J. Frias, *Food Chem.*, 2021, **360**, 130032.
- 139 K. A. Bermudez-Beltrán, J. K. Marzal-Bolaño, A. B. Olivera-Martínez and P. J. P. Espitia, *LWT-Food Sci. Technol.*, 2020, **123**, 109101.
- 140 M. Chakraborty, S. Budhwar and S. Kumar, *J. Food Process. Preserv.*, 2022, **46**, e17074.
- 141 A. Hedhili, S. Lubbers, E. Bou-Maroun, F. Griffon, B. E. Akinyemi, F. Husson and D. Valentin, *S. Afr. J. Bot.*, 2021, **138**, 406–414.
- 142 Z. Nizioł-Lukaszewska, D. Furman-Toczek, T. Bujak, T. Wasilewski and Z. Hordyjewicz-Baran, *Dermatology Research and Practice*, 2020, **2020**, 8197902.
- 143 H. T. Nhut, N. T. Q. Hung, B. Q. Lap, L. T. N. Han, T. Q. Tri, N. H. K. Bang, N. T. Hiep and N. M. Ky, *Int. J. Environ. Sci. Technol.*, 2021, **18**, 2173–2180.
- 144 A. Daina, O. Michielin and V. Zoete, *Nucleic Acids Res.*, 2019, **47**, W357–w364.
- 145 Y. Zhou, Y. Zhang, X. Lian, F. Li, C. Wang, F. Zhu, Y. Qiu and Y. Chen, *Nucleic Acids Res.*, 2022, **50**, D1398–D1407.
- 146 C. von Mering, L. J. Jensen, B. Snel, S. D. Hooper, M. Krupp, M. Foglierini, N. Jouffre, M. A. Huynen and P. Bork, *Nucleic Acids Res.*, 2005, **33**, D433–D437.
- 147 M. E. Smoot, K. Ono, J. Ruschinski, P.-L. Wang and T. Ideker, *Bioinformatics*, 2011, **27**, 431–432.
- 148 H. Berman, K. Henrick and H. Nakamura, *Nat. Struct. Mol. Biol.*, 2003, **10**, 980.

